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Aims: Oral isotretinoin is an effective treatment for severe acne that is teratogenic. On 1 
March 2009 funded access to oral isotretinoin in New Zealand was extended from 
dermatologist-only to also include prescriptions written by other prescribers where a 
dermatologist, vocationally registered general practitioner (GP) or nurse practitioner had 
obtained a Special Authority for this patient and medication. At the time of the change 
the Pharmaceutical Management Agency (PHARMAC) funded the development of an 
electronic decision support tool for primary care to support the safe prescribing and use 
of isotretinoin. Regular review of health outcomes was recommended to ensure the 
widening of funded access did not have negative effects on the health of the population.  
This study aimed to examine the previously identified inequitable isotretinoin access to 
determine if the change in funded prescriber influenced isotretinoin dispensing by 
ethnicity, age, gender, or deprivation level. The study also investigated terminations of 
pregnancy (TOPs) and potentially exposed live births following isotretinoin dispensing 
in women with different prescriber-types and compared these rates in women for whom 
the prescriber used the Best Practice Advocacy Centre (BPAC) isotretinoin decision 
support tool to support their prescribing with the rates in women whose prescriber did 
not. 
Methods: Retrospective prescription data for the 8 years from 1 March 2007 to 1 
March 2015 were analysed to determine how access to isotretinoin changed in the 
twelve month periods before and after the funding change. Using National Health Index 
(NHI) codes, maternity outcomes for women who had isotretinoin dispensed during the 
study period were analysed with regard to TOP and exposed live births. The rates of 
these adverse maternity outcomes were then compared for different prescriber-types and 
for women whose clinician used the BPAC decision support tool to guide their 
prescribing. 
Results: The use of isotretinoin has continued to increase since the change in funding 
and people living in more deprived areas (as defined by the NZDep Index), and Maori, 
Pacific and Asian people have had a proportionally larger increase in numbers accessing 




The TOP and exposed live birth rate following isotretinoin prescription is similar in 
women prescribed the drug by dermatologists and GPs. These clinicians prescribe the 
majority of isotretinoin in New Zealand and the rate of TOP within six months of an 
isotretinoin prescription is around 16-23% of that for all females aged 15-44 in New 
Zealand. However the female patients of other clinicians who prescribe isotretinoin 
much less frequently than dermatologists or GPs have TOPs within six months of 
isotretinoin at higher rates. Up to 16 live births per year in New Zealand are potentially 
exposed to isotretinoin with dermatologists, GPs and other clinicians all prescribing for 
the women involved. Use of the BPAC decision support tool to guide the prescribing of 
isotretinoin resulted in a lower rate of TOP and exposed births than occurred in patients 
where it was not used. 
Conclusions: Isotretinoin is proportionally more accessible to Asian, Maori and Pacific 
people and people in lower socio-economic groups than it was when funded only 
through dermatologists. However Europeans and the least deprived groups continue to 
be the people who use isotretinoin in the greatest numbers. 
GPs are now the largest group of isotretinoin prescribers in New Zealand but this has 
not resulted in higher rates of TOP or potentially exposed pregnancies than when 
prescribing was funded only through dermatologists. However female patients of other 
prescribers, who do not prescribe isotretinoin as frequently, have higher rates of TOP 
following isotretinoin dispensing and more potentially exposed live births. 
The BPAC Decision Support tool helped achieve better maternity outcomes for women 
accessing isotretinoin where it was used to guide prescribing. The challenge for health 
managers is to address barriers to its use, to invest in supporting all isotretinoin 
prescribers to use decision support, and to involve female patients in adhering to 




1 Introduction  
 
Oral isotretinoin is an effective treatment for severe acne that is known to be teratogenic 
and to cause an increased risk of spontaneous abortion when used during pregnancy.  
On 1 March 2009 funded access to oral isotretinoin in New Zealand was extended from 
dermatologist-only to also include prescriptions written by other prescribers where a 
dermatologist, vocationally registered general practitioner (GP) or nurse practitioner had 
obtained a Special Authority for this patient and medication. At the time of the change 
the Pharmaceutical Management Agency (PHARMAC) funded the development of an 
electronic decision support tool for primary care to support the safe prescribing and use 
of isotretinoin.  
Prior to this change in funding, a clear linear association between the use of isotretinoin 
and deprivation level has been shown in New Zealand with people living in the least 
deprived areas (as defined by NZDep Index) shown to be two and a half times as likely 
to access isotretinoin compared with people from the most deprived quintile1. Maori and 
Pacific people were also far less likely to access isotretinoin than those of other 
ethnicity (mainly NZ European)1.  
This study aimed to examine this previously identified inequitable isotretinoin access to 
determine if the change in funded prescriber influenced isotretinoin dispensing by 
ethnicity, age, gender, or deprivation level. The study also investigated terminations of 
pregnancy (TOPs) within six months of an isotretinoin prescription and potentially 
exposed live births with different prescriber-types and compared TOP rates in women 
for whom the prescriber used the Best Practice Advocacy Centre (BPAC) isotretinoin 
decision support tool to support their prescribing with TOP rates in women whose 
prescriber did not. 
The research questions for the study were: 
1) Has the use of funded isotretinoin in New Zealand from 1 March 2007 to 1 
March 2015 changed with regard to age, gender, ethnicity, and deprivation 
level?  
2) Has widened access to funded isotretinoin correlated to a change in the rate of 
TOP following isotretinoin dispensing and the number of potentially 
isotretinoin-exposed live births in New Zealand? 
Jenny McElroy    12 
 
3) Is there a difference in the TOP or exposed live birth rate between different 
isotretinoin-prescriber types in New Zealand from 1 March 2007 to 1 March 
2015? 
4) Is there a difference in the TOP or exposed live birth rate between women whose 
isotretinoin prescriber accessed the BPAC decision support tool for them and 
women whose prescriber did not? 
 
This study is important because review of the adverse maternity outcomes and access to 
isotretinoin has not been conducted since this funding change in order to evaluate the 
impacts on the health of New Zealanders. 
2 Background 
 
This chapter describes the condition of acne, its treatment and the use of oral 
isotretinoin in the treatment of severe acne including the risks associated with its use. 
2.1 Acne 
Vulgaris is the medical term for common2 and acne vulgaris is the common type of acne 
prevalent in 99% of acne cases.3 
2.1.1 Pathogenesis of acne 
Acne vulgaris is caused by the obstruction and inflammation of sebaceous follicles, 
which are a subtype of the pilosebaceous units of the skin. Sebaceous follicles consist of 
a sebaceous gland and a rudimentary hair growing out of the follicle. Figure 1 illustrates 




Figure 1: Structure of the Skin4  
Source: [Internet] 2014 [cited 2016 Apr 6]. http://www.clinimed.co.uk/Wound-Care/Education/Wound-
Essentials/Structure-and-Function-of-the-Skin.aspx 
The primary lesion of acne is a microcomedo, a microscopic lesion invisible to the eye. 
Some microcomedones evolve into either non-inflammatory comedo (open or closed), 
or inflammatory lesions such as papules, pustules, nodules (firm lumps) or cysts (fluid-
filled cavities). 
The formation of a microcomedo involves a complex interplay of four pathogenic 
factors: 
 altered follicular growth and differentiation (keratinisation),  
 hyperplasia of sebaceous glands with seborrhoea,  
 over-colonisation of sebaceous follicles with Propionibacterium acnes.  
 the host immune response and inflammation.5 
Propionibacterium acnes is a harmless member of the resident flora of the skin which 
proliferates in the environment of the microcomedo and is present in increased numbers 
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in people who have acne. The bacteria produce enzymes that hydrolyse sebum into free 
fatty acids and these stimulate inflammatory processes in the skin. As the wall of the 
follicle becomes inflamed, a reddened pimple appears on the skin surface. With 
increased sebum production, obstruction and colonisation of bacteria, the follicle 
ruptures and spills its contents into the dermis where the inflow of neutrophils causes 
the formation of pustules. If severe inflammation is present, this can lead to the 
formation of nodules and subsequent cysts.6 
2.1.2 Types of Acne 
The most common variants of acne are comedonal acne, papulopustular acne and 
nodular/conglobate acne. Comedonal acne involves non-inflamed lesions which are 
seen as blackheads, where comedones are open, and as whiteheads where they are 
closed. Clinically non-inflamed lesions develop from the subclinical microcomedo and 
closed comedones will often be inconspicuous with no visible follicular opening.7 
Papulopustular acne involves inflammatory lesions which may be either superficial (less 
than 5 mm in diameter) or, in more severe disease, deeper pustules or nodules. 
Inflammatory macules represent regressing lesions that may persist for many weeks and 
contribute significantly to the general inflammatory appearance of the acne.7 
Nodular acne involves nodules which are firm inflamed lesions that are painful by 
palpation and may extend deeply and over large areas. They frequently result in painful 
lesions, exudative sinus tracts and tissue destruction.7 
Conglobate acne is a rare but severe form of acne found most commonly in adult males 
with lesions usually on the trunk, upper limbs and buttocks. In contrast to ordinary acne, 
facial lesions are less common and it can persist to the sixth decade of life. Conglobate 
acne is characterised by multiple grouped comedones amidst inflammatory papules, 
tender, suppurativa nodules which may coalesce to form sinus tracts. Extensive and 
disfiguring scarring frequently results. 
Because acne treatment varies with severity and type, grading and classification of acne 
plays an important role in decision making for clinicians treating patients with acne. 
More than 25 different grading systems for the assessment of acne severity have been 
published3 including the Global Acne Grading System (GAGS) and the Comprehensive 
Acne Severity System (CASS). Global grading is based on photographic templates and 
descriptive text of primary lesions which is practical and clinically relevant but more 
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subjective, and therefore less reliable, than a system of lesion counting.8 Consequently 
there is a lack of consensus on the best acne classification and grading systems and no 
system is universally accepted as a global standard.3 
2.1.3 Epidemiology of Acne 
2.1.3.1 Prevalence 
Acne is estimated to affect 9.4% of the global population, making it the eighth most 
prevalent disease worldwide9 and the single most common reason persons aged 15 to 45 
years visit a dermatologist in the US.10 
2.1.3.2 Age 
The most common age for acne to occur is between 12 and 25 years11 but it persists into 
the 20s and 30s in around 64% and 43% of affected individuals respectively.12 The 
prevalence of adults aged > 25 years with acne is increasing and, in this age group, acne 
is more frequent and persistent in females.13,14 
2.1.3.3 Gender 
The World Health Organisation states that while most people are born either male or 
female (biological sex), they are taught appropriate behaviours for males and females 
(gender norms). For the purpose of this study, gender and sex will be used as synonyms. 
Self-reported studies have found higher rates of acne and lower rated quality of life in 
females15 which may be due to females being more sensitive to the presence of acne, 
particularly in its milder forms. Of all people whose principal diagnosis or reason for a 
visit to a registered physician is acne, 65% are female.10,16 
However a notable difference has been shown between the age distribution of males and 
females seeking medical attention for acne with two thirds of males being aged < 20 
years while most females are aged > 20 years. This suggests females aged > 20 years 
perceive acne as a continuing problem requiring medical treatment.10 
2.1.3.4 Severity 
In New Zealand a 2004 self-reported survey of 9570 adolescent students in Years 9 – 13 
at school found 67% of students reported acne and 14% reported ‘problem acne’.17 
Globally moderate to severe acne affects 15 to 20% of young people12 and is most 
common in teenagers post-puberty, with boys most frequently affected, particularly 




In the 2004 New Zealand self-reported survey of adolescent students, females, Pacific, 
and older students reported ‘problem acne’ more frequently than other groups.17 
However this may not reflect severity diagnosed with clinical assessment by a trained 
examiner as studies using clinical examination usually rate acne as more severe in males 
than in females.11 
2.1.3.5 Ethnicity 
It is unclear if ethnicity is associated with acne12 as the pathogenesis and clinical 
appearance of lesions is the same in patients of all ethnicities. In a global study across 
women in four cities (London, Los Angeles, Rome and Akita in Japan), the prevalence 
of acne was found to be 37% in African Americans, 32% in Hispanics, 30% in Asians, 
24% in Caucasians and 23% in Continental Indians leading authors to conclude acne 
prevalence and sequelae were more common in those people of darker skin types.18 On 
a per capita basis in the US between 1990 and 1997 there were 29 visits to a physician 
for the treatment of acne per thousand people per year that were Asian/Pacific Island, 20 
that were white and 8.8 that were Black.16 
Dark skinned people are more susceptible to increased pigmentation and the melanocyte 
responses to inflammation, which can complicate acne by leading to post-inflammatory 
hyperpigmentation, may be of greater concern to the patient than the acne itself. The 
increased risk of dyspigmentation and keloidal or hypertrophic scarring in more severe 
cases, means under-treatment in dark skinned patients should be avoided.19,20 
2.1.4 Treatment of acne 
This section will summarise the recommended treatments for the different severities of 
acne. Although I am not specifically addressing medication adherence in this study, it is 
worth noting that a clinic in the United Kingdom (UK) that analysed acne treatment 
adherence found the major reasons for missing treatment given by the patients were 
being fed up, forgetful or too busy.  Smoking cigarettes and drinking alcohol were 
shown to reduce medicine adherence.15 
2.1.4.1 Treatment of mild acne: 
Mild acne can usually be successfully treated with topical treatments obtainable in New 
Zealand without prescription.21 Suitable topical agents available in New Zealand in 
October 2015 include:  
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 Antiseptic washes with triclosan or benzoyl peroxide (Acnederm wash, Benzac 
AC Wash, Dalacin T Prewash, Oxy Daily Skin Wash)  
 Mild salicylic acid preparations to exfoliate and unplug the follicles (Neutrogena 
Oil-free Acne Wash and many others)  
 Benzoyl peroxide cream/lotion/gel (PanOxyl Acne Gel, Brevoxyl Cream, 
Clearasil Ultra Acne Cream, Benzac AC Gel). There seems to be no additional 
benefit to using higher strengths of benzoyl peroxide and lower strengths such as 
2.5% have fewer side effects.22 
 Azelaic acid (Skinoren cream, Acnederm medicated lotion, Azclear Action 
Lotion)  
 Hydrogen peroxide in stabilised cream (Crystacide, Crystaderm)  
 Tea tree oil products23,24 
Topical agents for mild acne that require a prescription include:  
 Antibiotics, such as clindamycin solution (ClindaTech) which is best used with 
benzoyl peroxide or azelaic acid to reduce the chance of antibiotic resistance. 
 Retinoids i.e. tretinoin (ReTrieve), adapalene (Differin)  
Combination prescription topical treatments including clindamycin / benzoyl peroxide 
(Duac) and adapalene/benzoyl peroxide gel (Epiduo) have the highest strength of 
recommendation for their use.7 
Many acne patients notice an improvement in their acne over summer25 and ultraviolet 
light has been used in the management of acne although concerns around skin cancer 
risk have limited this use.21 Lights and lasers26 including phototherapy with intense 
pulsed light (IPL) have been found to be safe and effective27 for mild to moderate acne 
when oral medications are unhelpful or unsuitable.  
2.1.4.2 Treatment of moderately severe acne 
Management of moderately severe acne may include the topical agents described above 
and at least three to six months oral medication. Suitable oral medications include: 
 Antibiotics such as minocycline, lymecycline, doxycycline or erythromycin 
although concomitant use of different topical and systemic antibacterials is not 
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recommended due to an increased likelihood of the development of bacterial 
resistance.28 When oral antibiotics are discontinued, control should be 
maintained long term by continuing topical therapy. 
 In females, oestrogens and antiandrogens such as Diane 35/Estelle 35 and/or 
spironolactone are helpful, particularly if there are signs of hyperandrogenism. 
This excessive male sex hormone (testosterone) may lead to signs of seborrhoea, 
acne, hirsutism, irregular menstruation, obesity and balding. 
 For resistant or persistent moderately severe acne, oral isotretinoin may be more 
suitable.21 
2.1.4.3 Treatment of Severe Acne 
Severe acne primarily requires treatment with oral agents, often with isotretinoin. Other 
treatments may also be used such as high dose oral antibiotics for six months or longer, 
topical treatments such as azelaic acid, benzoyl peroxide and adapalene, and 
antiandrogens in females. 
Table 1 shows the Strength of Evidence for acne treatments that are available in New 
Zealand based on the European Guidelines for the Treatment of Acne published in 
2012.7   
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2.1.5 Acne Recurrence 
Acne is considered a chronic disease because acne lesions typically recur for years.29 
Following successful acne treatment, maintenance therapy in the form of topical 
retinoids has been shown to minimise the potential for relapse and recurrence.29 This 
approach is now replacing the traditional use of oral antibiotics as maintenance therapy 
and repeat courses of the same antibiotic in the event of relapse.30 
The relapse rate after treatment with isotretinoin is the lowest of all acne therapies.7 
Even so, long-term remission is achieved only in 70 to 80% of patients having a single 
isotretinoin course.31 
The significant factors for relapse of acne following oral isotretinoin treatment include: 
 Stopping isotretinoin before acne has completely cleared 
 Macrocomedonal disease 
 Severity of acne 
 Excessive seborrhoea after finishing isotretinoin 
 Smoking 
 Younger age, under 14 years 
 Older age, particularly women over 25 years 




Isotretinoin is a retinoid first approved for oral use in New Zealand on 29 September 
1983.32 It is the cis configuration of tretinoin which is the acid form of vitamin A.33  
2.2.1 Who can prescribe isotretinoin in New Zealand 
Isotretinoin should be prescribed only by physicians who are experienced in the use of 
systemic retinoids and understand the risk of teratogenicity if used during pregnancy.34 
Risk management programmes have been implemented in different countries since the 
introduction of isotretinoin. However audits of their success have shown a lack of 
compliance and isotretinoin-exposed pregnancies have occurred despite these 
recommendations for use.35–38 No pregnancy prevention programme (PPP) has been in 
place in New Zealand. 
 
The National Health Index (NHI) code is a unique patient identifier that is assigned to 
every person who uses health and disability support services in New Zealand.39 The 
NHI provides information about gender, age, ethnicity and socioeconomic status of 
individual patients.   
 
Prior to 1 March 2009 funded oral isotretinoin was available in New Zealand only for 
prescriptions written by vocationally registered dermatologists many of whom did not 
have easy access to NHI codes to include on prescriptions. Consequently only 60% of 
isotretinoin prescriptions at this time can be linked to other health data although linear 
extrapolation has been previously used to allow for missing NHIs.1 Pregnancies did 
occur while women were taking isotretinoin under the dermatologist-only restricted 
isotretinoin prescribing. In the year to June 2008, 39 terminations of pregnancy (TOPs) 
in the six months following isotretinoin prescription were identified in New Zealand.40  
While funded access was available only through a dermatologist’s prescription it was 
recognised that people living in more deprived areas (as defined by the New Zealand 
Deprivation Index (NZDep)) were less likely to use isotretinoin, as were Maori and 
Pacific people.1 
2.2.2 Changes to the Access of Isotretinoin 
The Pharmaceutical Management Agency (PHARMAC) is the government entity 
charged with managing the publicly funded pharmaceutical budget in New Zealand. 
From 1 March 2009 PHARMAC added isotretinoin to the Special Authority System in 
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which a prescriber requests government subsidy of a drug for a particular person where 
the prescribing meets specific criteria. At this time PHARMAC widened funded access 
so vocationally registered general practitioners (GPs) and nurse practitioners were also 
able to make applications for a Special Authority to prescribe isotretinoin for their 
patients.  
The criteria for Special Authority approval of isotretinoin requires vocationally 
registered dermatologists, GPs or nurse practitioners working in a relevant scope of 
practice to have up to date knowledge of the safety issues around isotretinoin and for 
female patients to have been counselled and to understand the risk of teratogenicity. 
Among other criteria ensuring other acne treatments are given an adequate trial first or 
are contraindicated, prescribers must exclude the possibility of pregnancy before 
commencing isotretinoin treatment and female patients must be informed that they must 
not become pregnant during treatment and for one month after the completion of 
treatment.41  
Once a Special Authority application is approved for this patient, a Special Authority 
number is issued that is valid for one year after which it may be renewed. Renewals are 
also valid for one year and there is no limit on the number of renewals as long as all 
criteria are met. Once the Special Authority number is issued, any prescriber may 
prescribe isotretinoin for the patient as long as the number and its expiry date are quoted 
on the prescription. If the prescription is presented to a pharmacy without this number, a 
pharmacist can check the Special Authority database online and complete these details. 
2.2.3 Indications for Oral Isotretinoin 
The main indication for oral isotretinoin therapy is severe forms of acne or acne at risk 
of permanent scarring that is unresponsive to other therapy especially when the lesions 
involve the trunk.34 These severe forms of acne include nodulocystic acne, which is 
characterised by many nodules and cysts, and acne conglobata where interconnecting 
abscesses and sinuses (channels under the skin) can result in unsightly scars and groups 
of large macrocomedones and cysts filled with smelly pus.24  
 
While registered in New Zealand only for use in acne, dermatologists may rarely also 




Other off-label uses of oral isotretinoin include psoriasis, pityriasis rubra pilaris, 
condyloma acuminatum, granuloma annulare, Darier’s disease, systemic cutaneous 
lupus erythematosus and non-melanoma skin cancer.43 
2.2.4 Mechanism of Action 
The fundamental aspects of cell development where retinoids exhibit influence are in 
cell growth, differentiation, morphogenesis and apoptosis (a form of programmed cell 
death). Retinoids also inhibit tumour promotion and malignant cell growth, exert 
immune-modulatory actions and alter cellular cohesiveness through their ability to 
influence gene transcription and other mechanisms.31 
Isotretinoin is a synthetic stereoisomer of all-trans retinoic acid (tretinoin). When taken 
orally isotretinoin has a marked effect in severe forms of acne and is the only drug 
available that impacts all four pathogenic factors associated with acne.44 
1. Isotretinoin reduces sebaceous gland size (up to 90%) by arresting the cell cycle 
and inducing apoptosis within the sebaceous gland.  
2. This decreases the proliferation of sebaceous gland cells, disturbing their 
differentiation and suppressing sebum production.44,45  
3. Although isotretinoin does not directly affect Propionibacterium acnes, its 
inhibitory effect on sebum production leads to an alteration of the follicular 
microclimate, so that an indirect fall in the number of Propionibacterium acnes 
bacteria occurs.45  
4. In addition phospholipase, an enzyme that hydrolyses cell membrane 
phospholipids to generate inflammatory mediators such as arachidonic acid, is 
down-regulated by isotretinoin.46 
It is estimated isotretinoin affects over 500 genes; 300 being up-regulated and 200 
down-regulated. However the pattern of gene expression changes over time with an 
initial induction of apoptosis and cell cycle arrest, particularly in the sebaceous gland, 
followed by the skin adopting a wound-healing-like pattern, with subsequent repair and 
remodelling.31 
After just one week of treatment, distinctly different patterns of gene expression can be 
identified in people taking isotretinoin and hundreds of genes are changed by eight 
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weeks. Most genes that are down-regulated are lipid and sterol (cholesterol) 
metabolising enzymes within the sebaceous glands. The majority of genes that are up-
regulated affect structural proteins of the extracellular matrix such as collagens, fibulin 
and fibronectin. This is thought to lead to the known effects of retinoids in rebuilding 
extracellular matrix and may explain isotretinoin’s beneficial effects during acne 
resolution.46  
The size and structure of sebaceous glands returns to pre-treatment levels as early as 
two months after cessation of therapy and the rate of return is faster with lower doses of 
isotretinoin. Despite this, isotretinoin induces permanent remission of acne in the 
majority of cases. 
Oral retinoids have no effect on male fertility47 but isotretinoin is a recognised teratogen 
in females and causes a spectrum of congenital anomalies in more than 35% of exposed 
infants. The mechanism is thought to involve cytotoxic peroxyl free radical generation 
by metabolism with prostaglandin synthase resulting in toxic effects on the initial 
differentiation and migration of neural crest cells. The critical period of exposure is 
believed to be two to five weeks after conception.45,48,49 Isotretinoin has also recently 
been found to have a significant negative effect on ovarian reserve based on hormonal 
parameters, ovarian volume and follicle count in women with acne.50,51 
2.2.5 Dosing  
The recommended dose regimen in New Zealand for treatment with oral isotretinoin is 
to commence treatment at a dose of 10 – 20 mg/day for three to five months 53 and to 
continue until all acne lesions have resolved. Treatment should then be continued for a 
further two to four months to reduce the risk of relapse and help with the resolution of 
acne scarring.31 Based on clinical response and the tolerance of side effects, the second 
stage of treatment may be at a reduced dose such as 5 – 10mg per day. 
In some cases, acne actually worsens with initial isotretinoin therapy and, in patients 
with severe nodulocystic acne, an initial flare can result in permanent scarring. For this 
reason, it is recommended patients are started at the lower end of the recommended 
range then for treatment to be escalated as tolerated.54,55  
Clinical efficacy appears to be similar regardless of whether the dose is taken once or 
twice daily, but dividing the dose may reduce the incidence of adverse effects.56 Food 
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doubles the bioavailability of isotretinoin and the manufacturers recommend taking it 
with food. 
This dose regimen has been recommended in New Zealand since studies published 
since 2006 have demonstrated the effectiveness of lower doses of isotretinoin with 
fewer side effects.53,57,58,59 However these recommendations are cited in some 
international journals as still requiring long-term follow-up to authenticate this 
approach.60 
Dosing guidelines written prior to these studies, and still in place in the Medsafe 
Datasheets and New Zealand Formulary in 2015, recommend doses based on body 
weight such as 500 micrograms/kg daily (in one to two divided doses) initially for two 
to four weeks, increased if necessary to 1 mg/kg daily for 16–24 weeks.34,61 These doses 
are still in use in some countries62 although the recommended doses of isotretinoin are 
lower in Canada and the UK than in the United States (US).63 
The authors of dosage studies have advocated total cumulative doses from 120 mg/kg to 
greater than 220mg/kg per course to increase remission rates and prevent relapse.64,65 
However treatment endpoints varied widely and the evidence base for this 
recommendation is now challenged.66 It is now believed a shorter length of sebaceous 
gland suppression is more likely to explain instances of relapse in lower daily doses.31 
Consequently it is now recommended the dose and duration of oral isotretinoin should 
relate to clinical response with lower cumulative doses required for clearance of mild to 
moderate acne, and higher for more severe acne.66 
National dispensing data in New Zealand from July 2011 to June 2012 showed there 
were two most commonly prescribed isotretinoin doses. These were at 10 – 20 mg per 
day which was the dose for 63% of dispensings but there was a second most commonly 
prescribed dose of 80 – 90 mg per day which was prescribed in a further 22% of 
prescriptions. This usage in 2011 represented an average daily dose of 42 mg 
isotretinoin.53 It was not clear whether the 10 – 20 mg peak represented a deliberate 
strategy for low dose prescribing or whether prescribers were using lower doses in 
response to adverse effects.  
2.2.6 Adverse Effects 
With the exception of teratogenicity, most of the common adverse effects of oral 
isotretinoin are dose related and become more common and more severe with higher 
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doses.53 It is this predictable and dose-related nature of the adverse effects that has led 
to the development of varied dose regimens.54 At the higher dose of 1mg/kg per day, 
98% of patients report adverse effects while at doses below 0.25mg/kg per day, 50% of 
patients report no adverse effects at all, and in those who do, the effects are significantly 
less severe. 
Most frequently observed are symptoms associated with hypervitaminosis A. Dryness 
of the mucosa is generally most troublesome on the lips (chelitis), but may also occur 
on the nasal mucosa (leading to epistaxis), pharyngeal mucosa (leading to hoarseness) 
and dryness of the vaginal and/or anal mucosa. Dryness of the eyes can cause 
conjunctivitis and reversible corneal opacities. These mucocutaneous reactions can 
generally be managed with regular use of lip balms, moisturisers or artificial tears as 
needed. 
Temporary, reversible increases in liver transaminases may be significant in some 
patients67 and have occasionally made dose reduction or discontinuation necessary.34 
Increases in serum triglyceride and cholesterol levels, as well as decreases of high-
density lipoprotein (HDL), have been observed in patients taking oral isotretinoin 
particularly at high dosages and in predisposed patients. A risk of pancreatitis should be 
considered with triglycerides above 9 mmol/litre.61 However these changes are also 
dose related and return to normal on reduction of the dosage or withdrawal of the 
medicine.34 
Several blood dyscrasias have been reported with oral isotretinoin treatment including 
thrombocytopenia, thrombocytosis, neutropenia, leucopoenia, decreases in white and 
red blood cell counts including anaemia and an increased sedimentation rate.34,61,68 
Although no causal relationship has been established, elevated fasting blood sugars 
have been reported and new cases of diabetes have been diagnosed during isotretinoin 
therapy.34 
Isotretinoin is eliminated almost exclusively by hepatic metabolism and biliary 
excretion.34 In patients with severe renal insufficiency it is recommended treatment be 
started at a lower dose;34 one case report exists of suspected renal impairment induced 
by isotretinoin.69 
To address these potential risks and to ensure blood lipids, liver enzymes and blood cell 
counts remain within the healthy range during treatment, guidelines state patients 
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should have a full blood count, fasting lipids, renal and liver function tests performed 
within one month prior to being prescribed isotretinoin, after one month of treatment 
and three monthly during treatment.70,71 In patients who have diabetes, or are at high 
risk of developing diabetes, frequent determination of blood glucose levels is also 
recommended. 
Because abnormalities occur rarely72 and isotretinoin is usually prescribed for a younger 
population with generally good health, if follow-up monitoring at least once during a 16 
to 30 week course of treatment suggests no significant changes from a healthy baseline, 
repeated blood count, creatinine and glucose tests need only be repeated as clinically 
required.72,73 In New Zealand between July 2011 and June 2012, 47% of patients had all 
three baseline tests (blood count, liver enzymes and lipids) as recommended, but just 
13% of patients had all three tests both before and at least once during their course of 
isotretinoin treatment.73 
Night blindness is the most common and earliest symptom of vitamin A deficiency and 
isotretinoin inhibits retinal enzymes needed to synthesise vital components for normal 
vision. Isotretinoin-induced night blindness has been reported and some groups of 
patients, such as pilots, vehicle drivers and defence force personnel who require intact 
night vision, should be aware of this rare but potential side effect.74 
2.2.6.1 Teratogenicity 
The Australian categorisation system for prescribing medicines in pregnancy rates 
isotretinoin as a Category X medicine indicating it has such a high risk of causing 
permanent damage to the foetus that it should not be used in pregnancy or when there is 
a possibility of pregnancy.61 Of infants affected with isotretinoin embryopathy, over 
70% will have anotia/microtia (undeveloped or underdeveloped external ear) as 
illustrated in Figure 2. Over 25% of affected infants will have a smaller lower jaw 
(micrognathia) and >10% will have cleft palate. Heart defects are seen in about 40%, 
thymic defects in >30% of affected infants and retinal or optic nerve abnormalities in 





Figure 2: Spectrum of Microtia Severity  
Source: Derderian, Christopher A., Spectrum of Microtia Severity. [cited 2015 Sep 20]. 
http://www.drderderian.com/microtia/ 
Cognitive performance problems are seen even among children who have no evident 
structural defects, with 40% of all children prenatally exposed to isotretinoin having 
impaired learning abilities.75 Isotretinoin also increases the risk for miscarriage or 
stillbirth which occurs in up to 40% of exposed pregnancies and there is a doubled risk 
of premature birth.76 Current recommendations are that women must also avoid 
pregnancy for four weeks after stopping isotretinoin.  
2.2.6.2 Depression 
There are data to suggest a possible association between isotretinoin treatment and 
depression in 1-11% of patients, and evolving evidence that isotretinoin affects the 
neurotransmitters of the brain that have been known to cause depression.77 
However suicidal ideation is more common in people with severe compared with mild 
acne12 and this is the group more likely to have treatment with isotretinoin. Some 
studies have suggested oral isotretinoin is not a risk factor for depression78 and that it 
actually produces an improvement in symptoms of anxiety and/or depression in patients 
with mild to moderate acne.46,57 
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Consequently it is recommended healthcare providers discuss with their patients the risk 
benefit ratio of isotretinoin treatment and monitor at each visit for the development of 
signs of any negative effect on mood.77  
2.2.6.3 Inflammatory Bowel Disease 
Inflammatory Bowel Disease (IBD)  has been frequently reported in people taking 
isotretinoin but large studies have failed to show an increased risk of IBD among 
isotretinoin-exposed patients79–81, no causal relationship has been 
documented34,54,77,79,82–84 and in the US reporting has been recognised as 
disproportionally initiated by attorneys.85  
IBD is idiopathic and chronic intestinal inflammation seen as ulcerative colitis and 
Crohn’s disease. IBD can occur at any age but the peak incidence is between ages of 15 
and 30 years - the same peak as for the use of isotretinoin. There may also be a link in 
that both IBD and nodulocystic acne are inflammatory conditions.77 
Tetracyclines, including minocycline and doxycycline that are used to treat acne, have 
been associated with an increased risk of IBD. However it does not appear that use of 
isotretinoin itself increases the risk of IBD with antibiotics.77,79 This is important 
because many patients who are treated with isotretinoin have previously tried and failed 
other acne treatments such as oral antibiotics, and the decision support tool in New 
Zealand will not recommend oral isotretinoin for mild or moderate acne unless previous 
treatment has failed. However it remains important for clinicians to ask about personal 
or family history of IBD and to be alert to any possible early symptoms prior to starting 
and during treatment with isotretinoin.  
2.2.6.4 Drug Interactions 
A reduction in the effects of isotretinoin has been reported following significant alcohol 
intake86 but the clinical significance of alcohol intake during isotretinoin treatment is 
not known. The metabolism and pharmacokinetics of isotretinoin does not appear to be 
influenced by ethanol.87  
Tetracycline antibiotics should not be given with isotretinoin due to increased risk of 
intracranial hypertension.54,61 Where tetracyclines have been trialled to treat patients’ 
acne, they must be withdrawn before commencing oral isotretinoin.  
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Vitamin A supplements should also be avoided during systemic isotretinoin treatment 
due to additive toxic effects and because case reports exist of a condition similar to 
vitamin A (retinol) overdose.54 
The pharmacokinetics and ovulation suppressant effect of combined hormonal oral 
contraceptives are not affected by isotretinoin88 but it is unclear if isotretinoin affects 
the reliability of oral progestogen-only contraceptives so they are not generally 
considered reliable enough for use with isotretinoin.61   
2.3 Trends in Isotretinoin Usage in the Literature 
This section will describe the known differences in the use of isotretinoin by age, 
gender, ethnicity, socio-economic level and prescriber type both in New Zealand and 
globally. 
2.3.1 Age Differences 
There is little published data available to demonstrate the most common age for 
isotretinoin treatment in New Zealand. During 2005-6 in South Africa the median age 
of female patients using isotretinoin was 21 years and 18 years in male patients. This 
finding was a decrease in age from a previous study done almost a decade before.89 Data 
collected in 2001 when isotretinoin was only funded through dermatologists in New 
Zealand showed teenagers reported difficulty accessing treatment for acne in increasing 
numbers during the teenage years with a peak at age 16 years.17 However other studies 
have shown that when treatment is provided, younger patients are more likely to be 
adherent with their acne treatment which may impact the safe and successful outcomes 
of treatment in various ages.15 
2.3.2 Gender Differences 
Consideration of isotretinoin prescribing patterns by gender is important because the 
teratogenic side effects of isotretinoin that are present only in females may influence its 
use in this population group. If this risk creates a significant barrier to prescribing and 
use in females, greater isotretinoin use in males might be expected over and above the 
increased male tendency to more severe acne.11  
Difficulty accessing treatment for acne (not just isotretinoin) has been more commonly 
reported by female than male students17 and adherence to acne treatment is better in 
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females.15 Although per capita acne visits in the US are higher for women, men are 1.7 
times more likely than women to receive isotretinoin during an acne visit.16 Prior to 
2000 in the US female patients consistently received 50% of isotretinoin prescriptions63 
while in South Africa during 2005-6 female patients received 57% of isotretinoin 
prescriptions.89 To date, no published data has shown the use of isotretinoin by gender 
in New Zealand. 
2.3.3 Ethnicity Differences 
The European ethnic group is the largest in New Zealand with 74% of the population 
identifying themselves with one or more European ethnicities in the 2013 census. This 
had increased from 68% in the 2006 census but the increase was attributed to fewer 
people identifying themselves as 'New Zealander' in 2013. Other ethnic groups 
increased in size from the 2006 Census to 2013 Census including: 
• Mäori – 14.9% of the population in 2013 which was up from 14.6% in 2006  
• Asian – 11.8% of the population which had increased from 9.2% in 2006 
• Pacific peoples – 7.4% of the population which was up from 6.9% 
• Middle Eastern/Latin American/African (MELAA) – 1.2% of the population which 
had increased from 0.9%. 90 
Current consensus on the management of acne is that there is no difference in 
recommended treatment for people of different ethnicities.12 The survey of 6299 New 
Zealand adolescent students who had acne in 2001 found students of Pacific or Maori 
ethnic groups reported difficulty accessing treatment (not just isotretinoin) more 
frequently than New Zealand Europeans.17 In the US between 1990 and 1997 
isotretinoin was also less frequently prescribed to blacks than whites16 and cost, patient 
and provider biases were thought to be potential factors as well as racial differences in 
severity of acne. 
Similarly during the year ending June 2008, Maori and Pacific people were less likely to 
use isotretinoin than those of Other ethnicity (mainly New Zealand European)1 and 
during the year July 2011 to June 2012 since access was widened to include GPs and 
nurse practitioners, this showed no obvious change.91 
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2.3.4 Socio-economic Differences 
Medicine adherence to acne treatment is increased in employed people and people who 
do not need to pay for their acne prescriptions. However these groups of people also 
have a lower Dermatology Life Quality Index (DLQI) reflecting less impact on quality 
of life from their acne.15 Being employed and not paying for prescriptions were 
characteristics associated with increased medicine adherence and a lower DLQI.  
In New Zealand in 2008 when isotretinoin was funded only when prescribed by a 
dermatologist, there was a clear linear association between the use of isotretinoin and 
deprivation level. People from the least deprived quintile were more than two and a half 
times as likely to access isotretinoin compared with people from the most deprived 
quintiles. Relative ethnic inequalities compounded the socio-economic differences, so 
that Maori and Pacific people in the least deprived quintile used isotretinoin at about 
half the rate of other ethnicities in the most deprived quintile.1 The only study to review 
this data since the 2009 change in access to funded isotretinoin showed no obvious 
change to this association between the highest and lowest decile socioeconomic groups 
between July 2011 and June 2012 in New Zealand. 
2.3.5 Differences by Prescriber Type 
A 2008 analysis of isotretinoin prescribing arrangements around the world showed 
Australia, Denmark, Ireland, Sweden and the UK restricted prescribing to 
dermatologists only. The US, Canada, Argentina, Brazil, France, and Italy permitted 
any medical doctor to prescribe isotretinoin while in Bolivia, Mexico and Venezuela 
isotretinoin was an over-the-counter purchase with no prescription necessary. In the 
most recent European data available, published in May 2015 from six European 
databases in Norway, the Netherlands, Tuscany/Emilia Romagna regions of Italy, Wales 
and the rest of the UK, isotretinoin is still mainly prescribed by specialists.92 
In the US in 2010 dermatologists represented 72% of the prescribers registered in 
iPLEDGE 93 and they are shown to initiate over 80%  of isotretinoin prescriptions.16,94 
In the US, dermatologic mid-level providers such as physician assistants and nurse 
practitioners also prescribe isotretinoin. In 2010, 18% of the prescribers registered in 
iPLEDGE were these non-physicians.93 
In South Africa during 2005 and 2006, dermatologists prescribed 67% of isotretinoin 
prescriptions and GPs 29%. A 2011 study in the UK found isotretinoin could be 
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purchased from 42 out of 50 e-pharmacy websites without a valid prescription and when 
orders were placed on eight of these sites, seven arrived, all without any patient 
information leaflet.95 
Prior to March 2009, all funded oral isotretinoin prescriptions in New Zealand were 
written by dermatologists but one previous study showed that from July 2011 to June 
2012 58% of isotretinoin prescriptions originated from a GP.91 
2.3.6 International Systems to Prevent Pregnancy 
The greatest challenge in treating sexually active women of child-bearing potential with 
isotretinoin is contraceptive adherence and human error. The Pearl index, a measure of 
contraceptive failure for various methods of contraception, is generally less than 2.5 per 
100 women at one year96 meaning that women using one form of contraception during 
isotretinoin treatment may typically still conceive at around this rate. 
2.3.6.1 United States of America 
In the US in 2001, 5% of women aged 15-44 years had an unintended pregnancy but 
pregnancy rates during isotretinoin use are lower (0.3%).97 The United States Food and 
Drug Administration (FDA) has the authority to require a Risk Evaluation and 
Mitigation Strategy (REMS) from manufacturers to ensure the benefits of a drug or 
biological product outweigh their risks.98 Essentially, a REMS is a safety strategy to 
manage a known or potentially serious risk associated with a medicine and to enable 
patients to have continued access to those medicines by managing their safe use.99 
Since its approval in the US in 1982, several REMS have attempted to minimise foetal 
exposure to isotretinoin. The first US PPP was established in 1988 targeting prescribers 
and patients but reports of foetal exposure and the number of prescriptions among 
women of reproductive age continued to increase. In 2002 the System to Manage 
Accutane-Related Teratogenicity (SMART) was implemented with more stringent 
monitoring of pregnancy and prescription dispensing. The number of prescriptions for 
isotretinoin declined after SMART (and its generic equivalents) but there was not a 
substantial decrease in reports of foetal exposure. Consequently a more rigorous and 
uniform risk management program named iPLEDGE was implemented in 2006. 
The computer-based iPLEDGE programme requires more rigorous monitoring of 
contraceptive use with monthly pregnancy tests and healthcare providers, wholesalers, 
pharmacies and patients must all register in the programme. It allows real-time linkage 
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of pregnancy-test results for verification prior to isotretinoin dispensing.100 Following 
introduction of this programme the number of prescriptions decreased but resumed to 
pre-iPLEDGE levels within 10 months. Similarly a small increase in the proportion of 
female patients, particularly younger women, concomitantly using isotretinoin and 
contraceptives after the introduction of iPLEDGE was not maintained over time.94 The 
pregnancy rate among isotretinoin users in the US with iPLEDGE was estimated at 
2.7/1000 treatment courses and this was not significantly different from the previous 
SMART.38 Concerns over the high rates of prescriptions for isotretinoin that were 
denied due to failure to comply with iPLEDGE guidelines have prompted development 
and analysis of new patient support programmes.101  
2.3.6.2 Europe 
As the result of a European-wide review of isotretinoin use in 2003, a European Union 
(EU) PPP was agreed and, when surveyed in 2011, a PPP was in force in 21 of the 27 
member countries. Over 80% of these countries incorporated the following seven 
required elements of the formal EU review38,97  
1.Isotretinoin is contraindicated in pregnant women and should only be initiated in 
women of reproductive age who understand the teratogenic risk and the need for regular 
follow-up. 
2.Use of effective contraceptive measures from 4 weeks before isotretinoin initiation 
until 4 weeks after treatment discontinuation. At least one and preferably two 
complementary forms of contraception including a barrier method should be used. 
3.Pregnancy testing should be performed before, during and 5 weeks after 
discontinuation of isotretinoin. 
4.Isotretinoin should only be prescribed by or under the supervision of a physician with 
experience in the use of systemic retinoids. 
5.Prescription should be limited to 30 days of treatment and continuation of treatment 
requires a new prescription. 
6.Dispensing of isotretinoin should occur within a maximum of 7 days after prescribing. 
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7.Educational programmes for healthcare professionals including prescribers and 
pharmacists, and patients are in place to inform them about the teratogenic risk and to 
create awareness of the PPP. 
Despite this implementation, isotretinoin-exposed pregnancies occurred102 and so some 
European countries required additional pregnancy prevention measures. Consequently 
the consistent approach agreed in 2003 is no longer the universal approach for Europe.97 
The British Association of Dermatologists conducts regular audits of isotretinoin 
prescribing by its members. The most recent 2014 audit showed over 91% of women 
prescribed isotretinoin had signed the acknowledgement of PPP information indicating 
they had received appropriate information.103 
2.3.6.3 Other Countries 
In Canada, any physician can prescribe isotretinoin and a PPP requires female patients 
to sign an informed consent form and to agree to use at least two concurrent methods of 
birth control, one of which must be an oral contraceptive pill, during isotretinoin 
treatment. 
In Israel, only dermatologists can prescribe isotretinoin and all female patients must 
sign a consent form and agree in writing to use effective contraception during treatment 
and for an additional month afterwards. 
2.4 Termination of Pregnancy Trends 
This section will describe TOP numbers and trends in New Zealand and other countries 
as background to the consideration of TOPs following isotretinoin use. 
2.4.1 New Zealand 
All legal TOPs in New Zealand must be reported to the Abortion Supervisory 
Committee including TOPs that are not publicly funded. The data presented in this 
section, therefore is sourced from a more complete dataset than the National Minimum 
Dataset (NMDS) which includes only publicly funded TOPs. 
2.4.1.1 Trends in Number of TOPs 
Of the 13,137 induced TOPs in 2014, New Zealand residents accounted for 11, 971 
(91%), non-residents for 955 (7%) and 211 (2%) were not stated. The total number of 
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induced legal TOPs in New Zealand has been steadily declining since 2007 as 
illustrated in Figure 3. 
 
Figure 3: Total Number of Induced Legal TOPs 2004 - 2014 in New Zealand 
Source: Abortion Supervisory Committee, 2015, [cited 2016 Apr 10]. 
http://www.justice.govt.nz/tribunals/abortion-supervisory-committee/annual-reports/asc-annual-
report-2015 
The general TOP rate is the number of TOPs per 1,000 of the mean estimated 
population of women aged 15 – 44 years. The TOP rate in New Zealand from 2004 to 
2014 reflected the total number of induced TOPs during this time declining from 20.1 in 
2007 to 14.4 in 2014. 
2.4.1.2 Trends in Ethnicity of Women having TOPs 
In absolute numbers more European women have TOPs than any other ethnicity which 
would be expected as 74% of New Zealanders identify as European.90 Ethnic 
differences in TOP rates per 1,000 women have been identified in New Zealand as 
shown in Figure 4. People can belong to more than one ethnic group so the number of 
TOPs by ethnicity sum to more than the total number of TOPs. 
The TOP ratio is the number of TOPs per 1,000 known pregnancies. Known 
pregnancies include live births, stillbirths and induced TOPs combined, but do not 
include miscarriages. Asian women have previously had the highest TOP rates and 
ratios104 of all ethnic groups in New Zealand. However the TOP ratio for Asian women 
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has declined consistently since 2007 and in 2014 the number of TOPs per 1,000 known 
pregnancies for Asian women was similar to the ratios for Maori or Pacific women. 
 
Figure 4: Induced TOPs in New Zealand by Ethnicity Ratio 2007 – 2014 
Source: Abortion Supervisory Committee, 2015, [cited 2016 Apr 10]. 
http://www.justice.govt.nz/tribunals/abortion-supervisory-committee/annual-reports/asc-annual-
report-2015 
The Abortion Supervisory Committee of New Zealand noted the inclusion of long 
acting subcutaneous contraception to the already available intra-uterine devices may be 
one factor contributing to the steady decline in the number of TOPs.105 
2.4.2 TOP Trends in Other Countries 
The general TOP rate in low fertility countries has declined slightly in countries where 
data were available as shown in Table 2. Of the countries where data were available in 
2012, Sweden had the highest TOP rate with 20.7 TOPs per 1,000 women aged 15 – 44 
years. England, New Zealand and Wales had the second highest rate with just over 16 
while Norway and Denmark have a slightly lower rate with around 15 TOPs per 1,000 
women aged 15 – 44 years. Data available for 2011 showed France and the US also 
very similar to New Zealand, England and Wales in that year at around 17 TOPs per 
1,000 women aged 15 – 44.  
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Table 2: TOP Rate in Low Fertility Countries 2002-2013106 
 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Australia 20.3 19.7 19.3 - - - - - - - - - 
Denmark 14.1 14.7 14.4 14.5 14.4 14.8 15.5 15.8 15.8 15.1 14.8 14.3
England/Wales 16.2 16.6 16.9 17.0 17.5 17.9 17.6 17.0 17.1 17.2 16.4 16.5
Finland 11.0 10.8 11.3 11.1 10.8 10.7 10.7 10.7 10.5 10.9 10.4 10.4
France 16.8 16.5 17.1 16.7 17.5 17.4 17.1 17.3 17.6 17.4 17.3 - 
Germany 7.8 7.7 7.8 7.5 7.4 7.3 7.3 7.2 7.3 7.4 7.4 7.2 
Netherlands 8.7 8.5 8.7 8.6 8.6 8.6 8.7 8.8 8.7 8.7 8.5 8.5 
New Zealand 19.9 20.8 20.2 19.3 19.6 20.1 19.7 19.3 18.2 17.4 16.3 15.6
Norway 14.8 15.1 15.3 15.1 15.4 16.1 17.0 16.4 16.2 15.6 15.3 14.7
Scotland 11.1 11.6 11.8 12.0 12.5 13.1 13.3 12.4 12.2 11.9 11.9 11.2
Sweden 19.6 20.2 20.0 20.2 20.6 21.0 21.3 20.8 20.9 20.9 20.7 - 
US 20.5 20.2 19.7 19.4 19.9 19.4 19.4 18.5 17.7 16.9 - - 
 
Source: Statistics New Zealand, 2015, [cited 2016 Apr 10]. 
http://www.stats.govt.nz/browse_for_stats/health/abortion/AbortionStatistics_HOTPYeDec14.aspx 
2.5 Isotretinoin, Pregnancy and TOP 
This section will examine isotretinoin-exposed pregnancies in New Zealand before 
looking at what is currently known about the global situation. 
2.5.1 New Zealand 
Exposure to isotretinoin during pregnancy is not grounds for TOP in New Zealand.107 
The most commonly cited grounds for TOP are danger to the mental health of the 
woman. In 2014, 97.3% of all induced legal TOPs were for this reason with the second 
most common grounds for TOP significantly fewer: ‘handicapped child and mental 
danger’ accounting for 0.9% and ‘mental and physical health danger’ accounting for 
0.8% of all TOPs. 
TOP rates following isotretinoin in New Zealand need to be interpreted against the 
background of the previously described overall declining TOP rate. In 2011 Moodie et 
al40 reported on TOPs occurring while using isotretinoin in New Zealand and stated it 
would be important to regularly review these data to ensure the widening of funded 
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access did not have any unexpected negative effects on the health of the population. 
These researchers showed a linear correlation between all legal TOPs and deprivation 
quintiles with individuals from the most deprived areas having three times more TOPs 
than women living in the least deprived areas in the year ending June 2008. 
Therefore if the change in funding increased access to isotretinoin for women who 
already had more TOPs, it was anticipated that the rate of TOPs per patient treated 
could increase, in addition to wider use. This meant the absolute number of TOPs 
following isotretinoin dispensings would logically increase.40 
2.5.2 Europe 
In 2009 a questionnaire was sent to all 25 EU member states plus Norway and Iceland, 
and 22 responded. Since isotretinoin has been available in these countries, 393 
pregnancies exposed to isotretinoin have been reported, 143 since the introduction of 
the EU PPP in 2003. Five countries reported no exposed pregnancies and one country 
did not have data available. The most reported pregnancies in one country were 289 
including 65 which followed implementation of the current PPP.97 
 
Looking specifically at the Netherlands where a population based study of all 
isotretinoin exposed pregnancies > 16 weeks in the Netherlands from 1 January 1999 to 
1 September 2007 showed 2.5 pregnancies per 10 000 were exposed to isotretinoin 
despite the PPP and 60% of these women started isotretinoin while already being 
pregnant.38 This figure did not include spontaneous abortions before 16 weeks or 
elective TOPs so these results probably underestimate the number of isotretinoin-
exposed pregnancies and their consequences. The PPP was implemented in 1988 in the 
Netherlands and this nationwide study showed a lack of full compliance to the 
isotretinoin PPP. 
2.5.3 Other Countries 
Between 1984 and 2002 in Canada there was an annual pregnancy rate during 
isotretinoin treatment of 32.7 per 1000 person-years of treatment. Of women who 
became pregnant while on isotretinoin, 84% had a TOP, 3% had a spontaneous 
abortion, 2% had trauma during delivery resulting in neonatal deaths and 10% had a live 




2.6 Clinical Decision Support for Isotretinoin Prescribing 
2.6.1 Decision-making software for primary care 
Decision-making software has been made available in many areas of healthcare to 
provide clinicians with additional support beyond referencing guidelines in both chronic 
and acute care settings. Decision support tools are becoming ubiquitous throughout 
New Zealand primary care with goals to improve access, quality of care and cost-
effectiveness.109 However their use has rarely been carefully evaluated to determine if 
they achieve these aims or improve outcomes.  
Best Practice Advocacy Centre (BPAC) electronic decision support modules are used 
by 76% of general practices and 85% of GPs.110 International evidence of whether 
point-of-care decision support improves patient care has been equivocal. While benefit 
of improved processes of care and guideline adherence has been shown, there has been 
little assessment of risks (costs and interruption to workflow) or benefit to patient 
outcome. Systematic reviews of the decision support literature conclude there is a 
shortage of well-designed trials of decision support that provide assessments of their 
effectiveness in changing patient outcomes as well as in changing clinician 
behaviour.111–113  
There has been no research investigating the impacts of any chronic care BPAC 
Decision Support modules on clinical behaviour and patient outcomes in New Zealand, 
although the use following transient ischaemic attack/stroke has been shown to improve 
guideline adherence, safely reduce treatment cost, achieve positive user feedback, and 
may reduce cerebrovascular and vascular event risk.110 
Decision making software for primary care may aid GPs who had previously not 
prescribed isotretinoin to recognise when isotretinoin treatment is appropriate and 
promote treatment initiation rather than referring for specialist review as previous 
funding regulations had required. One of the benefits of decision support tools is that 
they are inherently educational, providing GPs with guideline based advice which can 




2.6.2 Acne/Isotretinoin Decision Support in New Zealand 
At the time of the isotretinoin funding change, PHARMAC funded the development of 
an electronic decision support tool for the treatment of acne. This tool was made 
available to primary care clinicians throughout New Zealand to support the safe 
prescribing and use of isotretinoin. This tool was developed and supplied by BPAC CS 
Ltd and was fully integrated with the main practice management systems in use. The 
tool required a patient’s NHI code to be recorded and allowed clinicians to easily access 
information on contra-indications, dosage guidelines, recommended laboratory tests, 
patient consent forms and patient information sheets relevant to their current patient.  
2.6.2.1 Use of the BPAC Isotretinoin Decision Support Tool 
The decision support tool is a Web-based software programme accessed via an icon on 
the GP’s Practice Management System. The icon takes the User to the BPAC Main 




This will take the User to the landing page for the Module which is the Introduction tab 
and explains the process for prescribing and managing patients on isotretinoin. 
 
The User then clicks the next tab to view the Red Flags. The contraindications and 
situations where prescribing must only be done with caution are described on this page. 
The blue information icons provide Users with further information on some of the terms 




If the clinican confirms isotretinoin is not contra-indicated, they move to the Test 
Required tab where an explanation of the recommended tests required is available. This 
page is gender specific and so includes the Pregnancy test information for all female 
patients. The Glucose Test Required question defaults to No with a note that glucose 
testing may be required for patients predisposed to diabetes. 
 
The final tab is a Patient Information tab. On this tab there is a link to the Isotretinoin 
Consumer Medicine Information sheet and a gender-specific patient information sheet. 




There is also a gender specific Patient Consent Form which includes the teratogenicity 
and contraceptive issues for female patients. Clicking on the link to the Isotretinoin 
Patient Consent Form will produce a copy of a gender specific form, with the first three 
statements only included for female patients. 
A copy of the blank form as sighted by the User will be written back to the Patient 
Management System if it is opened, however many GPs chose to print the form, sign it 
personally and have the patient do so as well. This was then routinely scanned back into 




Having completed the Consent Form, clicking ‘Print/Save’ would automatically create a 
copy of the Laboratory Request Form. The GP would choose the appropriate Laboratory 
service and had the option of adding or removing any of the laboratory services 
requested before printing.
 





The technical aspects involved in processing these steps take 40 seconds. However the 
module is likely to stimulate appropriate discussion around the use of a teratogenic 
agent requiring two forms of contraception in females and some blood monitoring 
which may extend the consultation time. 
The decision support tool aids clinicians in ensuring they have considered the contra-
indications and appropriate laboratory tests while having easy access to patient 
information and appropriate consent forms in a readily-accessible format during the 
consultation.  
In the only randomised controlled trial involving a BPAC decision support tool to date, 
GP feedback was positive about the Stroke/TIA tool with all 63 GP respondents saying 
they would use that tool at least some of the time114. In that study comments included 
statements such as “allows quick evidence-based decision making in a short 
consultation and no need to duplicate notes or letters.” 
Other electronic information sources have been available to clinicians in some regions 
in addition to the BPAC Decision Support tool but these have not been nationally 
available or integrated with a unique patient identifier to provide information tailored to 
specific patients. For example, in Canterbury HealthPathways in 2014 there were 154 
searches on the word isotretinoin and 960 on the words severe acne (personal 
communication: User Documentation Specialist, Streamliners, 2015). Primary care 
clinicians in the Canterbury region who had access to HealthPathways may not 
routinely have felt the need to access the BPAC tool for decision support when 
prescribing isotretinoin.    
One significant difference with the BPAC Isotretinoin Decision Support tool is the way 
it involves patients. As has been pointed out by dermatologists, closer adherence to 
guidelines by clinicians alone will not always avoid isotretinoin-exposed pregnancies.115 
Whereas many similar decisions support tools promote guideline adherence for 
clinicians, this module involves patients with a consent form and information leaflets 
that can be easily printed and personally discussed with the patient during the 
consultation. These active methods of disseminating information have been empirically 
shown to be more effective than passive strategies such as printed pamphlets or 
websites used alone.116 As patient compliance with recommendations around 
contraception and pregnancy-prevention is essential to successful management of 
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teratogenic risk, the value of the module is increased by its provision of opportunities to 
enhance these processes.  
This study provides a retrospective comparison of rates of TOP and exposed birth in 
patients cared for by clinicians who accessed the tailored decision support tool for their 
isotretinoin patients, to rates of TOP and exposed birth for patients of clinicians who did 
not. This will be the first whole population audit for the use of a decision support tool in 
New Zealand and the first to examine differences in the rate of an undesirable patient 
outcome following the use of decision support when prescribing a specific drug.  
2.6.3 New Zealand National Collections 
The Ministry of Health collects data from different parts of the health sector in New 
Zealand and makes this available to stakeholders and researchers via National 
Collections. The national collections of health and disability data provide health 
information on doctor’s visits, laboratory and pharmaceutical claims, immunisations, 
cancer, maternity, hospital events, mortality, mental health, and medical warnings. 
These data are linked by the universal use of the NHI code to identify individuals and 
the encounters they have with the health system.117 
2.7 Research Objectives  
The overall aim of this study is to understand the prescribing trends and adverse 
maternity outcomes of isotretinoin in New Zealand from 1 March 2007 to 1 March 
2015. The study will answer the following research questions. 
1) Has the use of funded isotretinoin in New Zealand from 1 March 2007 to 1 
March 2015 changed with regard to age, gender, ethnicity, and deprivation 
level?  
The null hypothesis is that there is no significant change in the use of oral isotretinoin 
by age, gender, ethnicity or deprivation level between 1 March 2007 and 1 March 2015. 
2) Has widened access to funded isotretinoin correlated to a change in the rate of 
TOP following isotretinoin dispensing and the number of potentially 
isotretinoin-exposed live births in New Zealand? 
The null hypothesis is that there is no significant difference in the rate of TOP following 
isotretinoin dispensing and the number of potentially isotretinoin- exposed live births in 
New Zealand women since widened access was introduced on 1 March 2009. 
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The study will also identify the proportion of isotretinoin prescribers who were 
dermatologists or GPs or others in each year during the study period from 1 March 2007 
until 1 March 2015.  
3) Is there a difference in the rate of TOP following isotretinoin or the number of 
potentially isotretinoin-exposed live births between different prescriber types in 
New Zealand from 1 March 2007 to 1 March 2015? 
The null hypothesis is that there is no significant difference in the rate of TOP following 
isotretinoin or the number of potentially isotretinoin-exposed live births by prescriber 
type in New Zealand from March 2007 to March 2015. 
4) Is there a difference in the rate of TOP following isotretinoin or the number of 
potentially isotretinoin-exposed live births between women whose prescriber 
accessed the BPAC decision support tool for them and women whose prescriber 
did not? 
The null hypothesis is that there is no significant difference in the rate of TOP following 
isotretinoin or the number of potentially isotretinoin-exposed live births between those 
women whose prescriber used a decision support tool for them and those whose 




3 Research Design, Data Sources and Methods 
This study examined retrospective annual isotretinoin usage data from 1 March 2007 to 
1 March 2015. The Ministry of Health’s Information Group operates the National 
Collections for health and disability information in New Zealand. These data are 
available to researchers and the public on request118 and provided one data source for 
this study.  In addition to the National Collections, the BPAC Isotretinoin Decision 
Support module usage information was also obtained from BPAC CS LP. Descriptive 
analysis was used to interpret the findings from matching these data sources. The 
datasets were given the following names: 
1. Isotretinoin Usage Dataset 
2. Maternity Dataset 1 
3. Maternity Dataset 2 
4. Decision Support Usage Dataset 
5. Decision Support and Maternity Data matched 
This chapter will describe how the data from these sources was cleaned and matched for 
the purposes of this study. Further details of the methods employed and examples to 
illustrate the processes implemented are shown in appendix A and B. Figure 5 illustrates 




Figure 5: Method of Cleaning Datasets to Determine TOPs and Potentially 
Exposed Live Births in Women Dispensed Isotretinoin where Decision Support 
was used 
 
3.1 Isotretinoin Dispensing and Demographic Data Sources 
NHI codes were used as the unique patient identifier to link the information from the 
different data sources in this study. The NHIs in the various sources were consistently 
encrypted by the Ministry of Health enabling a detailed picture of health information for 
each encrypted NHI to be determined. NHI codes were only ever visible to researchers 
in encrypted form.  
The national dataset used to provide isotretinoin dispensing data in this study was the 
Pharmaceutical Collection. This data warehouse contains prescription claim and 
payment information from community pharmacists’ subsidy claims and is jointly owned 
by the Ministry of Health and PHARMAC.118 Demographic data such as age, gender, 
ethnicity and socioeconomic status (deprivation quintile) of people in this study were 
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obtained from the Primary Health Organisation (PHO) Enrolment Collection. The 
ethnic code groups used in the National Collection are shown in Table 3. 
Table 3: Ethnic Code Groups used in the National Collections119 
Ethnic Code Group Ethnic Code Group Description 
1 European 
2 Maori 
3 Pacific Peoples 
4 Asian 
5 MELAA* 
6  Other Ethnicity 
*MELAA = Middle Eastern/Latin American/African 
If people identified more than one ethnicity, they were allocated to a single ethnic 
group, based on the prioritised order of Mäori, Pacific, Asian and European/Other.120  
Socioeconomic deprivation in New Zealand is defined by the New Zealand Index of 
Deprivation based on the area of residence of an individual. It is based on census 
variables such as income, home ownership, employment, qualifications, family 
structure, housing, access to transport and communications.121 The Index represents the 
relative socio-economic deprivation of an area and does not directly relate to 
individuals.   
3.1.1 Cleaning Isotretinoin Usage Data 
1. Isotretinoin Usage Dataset 
The data provided for each record in the Isotretinoin Usage Dataset and its source is 
described in Table 4. This dataset was sorted and filtered to analyse the gender, 
ethnicity, age, deprivation quintile and the number of days’ supply at each isotretinoin 
dispensing. The isotretinoin usage data was provided in an excel spreadsheet covering 
all dispensings of isotretinoin from March 2007 to February 2015 (inclusive). It was 
provided with a separate worksheet for the isotretinoin dispensings in each year ending 
1 March. Because some individuals had isotretinoin dispensed in more than one year, 
their NHI code was included on more than one of these annual tabs, meaning the total 
number of people dispensed isotretinoin could not be totalled across the annual 
worksheets. Consequently data analyses on the total data set were carried out using 
Structured Query Language (SQL). 
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Table 4: Data Fields and Data Source contained in Isotretinoin Usage Dataset 
Data Source Data Field Definition 
Pharmaceutical Collection Date Dispensed Date of Each Dispensing 
Pharmaceutical Collection  Chemical Name  Isotretinoin 
Pharmaceutical Collection  Formulation Name Cap 10mg or 20mg 
Pharmaceutical Collection  Encrypted NHI  
Pharmaceutical Collection  Number of Items  
Pharmaceutical Collection  Provider Type Medical or other 
Pharmaceutical Collection  Repeat Sequence 
Number 
To indicate if this was the first, 
second (etc) time isotretinoin 
was dispensed off one 
prescription 
Pharmaceutical Collection  Dose  The number of capsules per dose 
Pharmaceutical Collection  Days’ Supply Days of Isotretinoin Treatment 
supplied 
Pharmaceutical Collection  Sex Code  
Pharmaceutical Collection  Patient Age at 
Dispensing 
 
PHO Enrolment Collection  Ethnic Group Code Level 1 Ethnic Code 
PHO Enrolment Collection Deprivation 
Quintile 
 
These data were used to determine the number of patients dispensed isotretinoin in each 
year from 1 March 2007 to 2015. The change in total numbers of patients from one year 
to the next was then used to determine the rate of change in the number of patients 
accessing funded isotretinoin for each year before and after 1 March 2009.  
Rates of TOP and exposed live birth per prescriber-type were calculated from the 
number of females who had isotretinoin prescribed by each prescriber-type during the 
study period.  
3.2 Maternity Data Sources 
The national collection used to provide maternity and birth information in this study 
was the NMDS of hospital events. The NMDS includes public and private hospital 
discharge information including coded clinical data for inpatients and day patients.117 It 
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provides statistical, demographic and clinical information about publicly funded 
maternity services that are recorded in Diagnosis Related Groups. These Diagnosis 
Related Groups are derived from the International Statistical Classification of Diseases 
and Related Health problems, 10th Revision, Australian Modification (ICD-10-AM 
codes) which is the clinical coding classification developed by the World Health 
Organisation and used in New Zealand hospitals.122 Chapter XV of the ICD-10-AM 
codes includes all codes relating to pregnancy, childbirth and the puerperium (O00-
O99) with pregnancies with abortive outcomes covered by O00-O08. Chapter XXI 
includes codes relating to factors influencing health status and contact with health 
services (Z00-Z99) with codes for outcome of delivery covered by Z37 as a category 
intended for use as an additional code to identify the outcome of delivery on the 
mother’s record.122 
All TOPs carried out in public hospitals, as well as TOPs that are publicly funded and 
carried out in private hospitals, are reported in this way. These data were delivered from 
the Ministry of Health for prescriptions dispensed for the period 1 January 2007 to 30 
June 2015. However the study period was prescriptions dispensed for the years ending 1 
March 2008 through to 1 March 2015.  
This study obtained information on the number of days’ supply of isotretinoin provided 
at each dispensing. Consequently where more than 30 days of isotretinoin was 
dispensed, the extra period of supply extended the time during which a TOP may be 
linked to isotretinoin, or a subsequent live birth is potentially exposed to isotretinoin.  
3.2.1  Cleaning Maternity Data 
This section will describe the process of identifying the relevant data required to 
achieve the aims of this study and how it was cleaned from the datasets received. 
Pregnancies with abortive outcomes are classified as O00 – O08 ICD-10-AM Version 
for 2016. Codes of O00 to O03 are ectopic pregnancies, hydatidiform moles, other 
abnormal products of conception and spontaneous abortion.  Codes O04 to O07 are 
used for TOPs while O08 are complications following TOP, ectopic and molar 
pregnancy. This meant the data I received will allow future analysis of the adverse 
maternity outcomes following isotretinoin prescriptions, but this analysis did not form 




Previous analysis has assumed that isotretinoin prescriptions within the six months 
preceding TOP suggest a possible link between isotretinoin use and TOP. This period 
was considered sufficient to take into account prescription length, one month post 
medication period, time to awareness of pregnancy and time to organise TOP.40 
The current recommendation is that women should not become pregnant for at least a 
month following the end of isotretinoin treatment. People encountering health services 
in circumstances related to reproduction are classified as Z30 – Z39 in ICD-10-AM 
Version for 2016. Codes starting from Z37 are used as additional codes to identify 
delivery outcomes on the mothers’ records such as single live birth, single stillbirth, and 
twins both live born. 
To identify the relevant events for my study from the maternity data provided, I filtered 
the data to the following subsets for individual analysis: 
 TOPs within six months (183 days) of an isotretinoin prescription where the 
prescription quantity was less than 31 days’ supply 
 TOPs within seven months (183 + 30 = 213 days) of an isotretinoin prescription 
where the prescription quantity was 31 - 60 days’ supply 
 TOPs within eight months (183 + 60 = 243 days) of an isotretinoin prescription 
where the prescription quantity was more than 60 days’ supply 
 Live Births within 340 days of an isotretinoin prescription where the 
prescription quantity was up to 30 days’ supply (30 days treatment period + 30 
days break + 280 days pregnancy) 
 Live Births within 370 days of an isotretinoin prescription where the 
prescription quantity was 31 - 60 days’ supply (60 days treatment period + 30 
days break + 280 days pregnancy) 
 Live Births within 400 days of an isotretinoin prescription where the 
prescription quantity was more than 60 days’ supply (90 days treatment period + 
30 days break + 280 days pregnancy) 
For the purposes of filtering data for this study, any prescription for less than 31 days’ 
supply was treated as 30 days’ treatment period. For any period of supply 31-60 days’ 
supply, the treatment period was filtered as if it had been for 60 days’ supply. Any 
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period of supply >60 days was filtered as if it had been for 90 days’ supply. The small 
numbers of related dispensings that fell into this category meant each was then 
individually examined to understand the potential for isotretinoin exposure. 
2. Maternity Dataset 1 
Maternity Dataset 1 was separated into calendar years for the period from 1 March 2009 
to 31 December 2014 and matched isotretinoin prescriptions with females who had a 
maternity event within 12 months. The data had 3 worksheets for each calendar year 
and is shown in Table 5.  
Table 5: Data Source and Data Fields contained in Maternity Dataset 1 
Worksheet Name Data Source Data Field 
NMDS (calendar year) NMDS  Encrypted NHI 
 NMDS  Date Event Ended 
 NMDS ICD-10-AM Code* 
 NMDS  Diagnosis Related Group codes*  
Prescription Data 
(calendar year) 
Pharmaceutical Collection  Number of Prescriptions 
 Pharmaceutical Collection Encrypted NHI 
 Pharmaceutical Collection Dates Isotretinoin Dispensed 
 Pharmaceutical Collection Chemical Name 
Demographic Data 
(calendar year) 
PHO Enrolment Collection Encrypted NHI 
 PHO Enrolment Collection  Ethnic Group 
 PHO Enrolment Collection  Age in Years 
 PHO Enrolment Collection DHB Name 
 PHO Enrolment Collection Deprivation Quintile 
*Prior to 2012 NMDS data used Diagnosis Related Group codes and from 2012 the 
ICD-10-AM code was used. 
Sorting the data by NHI codes allowed the following details to be analysed: 
1) All maternity outcomes that occurred for each woman who had an isotretinoin 
prescription in the previous 12 months and when each maternity event ended.  
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2) The date of all the isotretinoin dispensings for each NHI code in each calendar year 
between April 2009 and the end of 2014.  
The matched data over time provided a summary of each woman’s journey with regard 
to isotretinoin prescriptions and subsequent maternity outcomes. The maternity codes 
were then grouped into categories of medical TOPs and live births. 
3. Maternity Dataset 2 
A second Maternity Dataset was obtained because prescriber type was not present in 
Maternity Dataset 1 and the isotretinoin dispensing date in each 12 month period before 
and after 1 March 2009 was required to fully address the research questions. This was 
obtained in Maternity Dataset 2 which contained the dates of isotretinoin dispensings 
for women having maternity outcomes within 15 months of any isotretinoin dispensing 
(the maximum period that could be accessed) and is shown in Table 6. 





PHO Enrolment Collection Encrypted NHI 
PHO Enrolment Collection Age at dispensing 
PHO Enrolment Collection Ethnic Group 
PHO Enrolment Collection DHB Name 
PHO Enrolment Collection Deprivation Quintile 
Pharmaceutical Collection Encrypted NHI 
Pharmaceutical Collection Date Dispensed 
Pharmaceutical Collection Prescriber Specialty 
BPAC Decision Support Date 
NMDS Date Maternity Event Ended 
NMDS  Days between Dispensing and Maternity Event 
NMDS  ICD-10-AM Code* 
NMDS  Diagnosis Related Group Codes* 
NMDS  Clinical Code Chapter 
NMDS  Clinical Code Description 
*Prior to 2012 NMDS data used Diagnosis Related Group codes and from 2012 the 
ICD-10-AM code was used. 
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This allowed the number of days between maternity outcomes and the last isotretinoin 
dispensing to be calculated.  If the maternity outcome was a TOP women who had been 
dispensed isotretinoin within six months of the TOP were identified. Where the time 
between isotretinoin and TOP was 6-8 months the days’ supply of isotretinoin was also 
obtained as longer treatment periods may have meant these prescriptions were also 
linked (see linking databases in Section 2.4). The analytic approach to matching 
isotretinoin prescription and maternity event data is described in Appendix A. 
3.3 Decision Support Data 
The BPAC Decision Support tool includes a consent form from the GP confirming that 
patients whose care is guided by the tool understand that aggregated, non-identifiable 
information from this form may be used for population based health research as shown 
in Figure 6.  
 
Figure 6: Confirmation patient understands use of these data for research 
If the ‘No’ box was ticked at this stage of the module, a pop-up window appeared as 
shown in Figure 7. The clinician could still access the resources in the module and 
Jenny McElroy    58 
 
continue the patient’s care in the usual way, but would exit the module before any 
information was written to the patient record or the database used for this research. 
 
Figure 7: Pop-up window to prevent data being kept if patient does not agree to 
non-identifiable information being used for health research.  
If permission was granted by the patient and recorded by the clinician in this way, the 
extraction of the Isotretinoin Decision Support module usage data was considered to 
have been given. The NHI codes in the decision support data are unencrypted and were 
never available for this research. Instead, the NHI codes were sent directly to the 
Ministry of Health for encryption using the same process as used for NHI encryption of 
other data from the Ministry of Health Collections. This enabled NHI codes of patients 
for whom the decision support module was accessed, and the date(s) it was used, to be 
matched with the data from Pharmaceutical and NMDS Collections.  
Whereas many other decision support tools ensure guideline adherence for clinicians, 
the BPAC Isotretinoin Decision Support tool involves a patient consent form and 
patient information leaflets in an easily accessible form to print and personally discuss 
with the patient. Where patient compliance with recommendations around contraception 
and pregnancy-prevention is so essential to successful management of teratogenic risk, 
the module provides opportunities to enhance these processes during the consultation.  
3.3.1 Cleaning Decision Support Data 
The decision support usage data were called ‘Decision Support Usage Dataset’ shown 
in Table 7 and were supplied with the last dispensing date for each NHI code for the 
time period 1 January 2007 to 30 June 2015. This meant it was not possible to restrict 
the dataset to the study period of 1 March 2007 to 1 March 2015 only as dispensings 




4. Decision Support Usage Dataset 
The data source and data fields in the Decision Support Usage Dataset are shown in 
Table 7. 





Pharmaceutical Collection Encrypted NHI 
Pharmaceutical Collection Last Dispensing Date 
PHO Enrolment Collection Sex Code 
PHO Enrolment Collection Ethnic Code 
PHO Enrolment Collection Age at Dispensing 
PHO Enrolment Collection Deprivation Quintile 
BPAC Decision Support Usage Data Encrypted NHI (if Decision Support was used) 
BPAC Decision Support Usage Data Decision Support Date 
NMDS Date Event Ended 
NMDS  ICD-10-AM Code* 
NMDS  Diagnosis Related Group Codes* 
*Prior to 2012 NMDS data used Diagnosis Related Group codes and from 2012 the 
ICD-10-AM code was used. 
The data were filtered to find the total number of patients who had decision support 
used for their care over the study period. It was not possible to determine the total 
number of times the decision support module was used before an isotretinoin 
prescription because this dataset contained only the last dispensing date during the 
larger timeframe, including a few months either side of the study period.  
The number of TOPs or exposed live births where decision support was ever used prior 
to the related dispensing could be divided by the total number of females whose 
prescriber ever accessed decision support to give a crude TOP rate and potentially 
exposed birth rate for women where decision support had ever been used. This was then 
compared to the same rate in all females accessing isotretinoin and in females who did 
not ever have the decision support module used for them. As the numbers involved were 
very small, individual analysis of the timing behind the decision support use in these 
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women was then done to determine which women actually had the decision support tool 
used for the related prescription before their TOP or exposed birth. 
 
Linking Databases 
This section will describe how the information from the various datasets was linked to 
analyse the circumstances around the isotretinoin dispensing, use of decision support 
and adverse maternity outcomes. Specific examples to illustrate the processes involved 
are included in Appendix B. 
3.3.2 Decision Support and Maternity Data matching 
The consistent Ministry of Health encryption process allowed the BPAC Decision 
Support data to be linked to the encrypted NHI codes of the NMDS, PHO Enrolment 
and Pharmaceutical Collections. The data were obtained with decision support dates 
detailed and the days between the isotretinoin prescription and the maternity event were 
calculated to create an additional field.  
Once these databases were linked, the following outcomes were obtained: 
 TOPs between 183–213 days for prescriptions of 31-60 days’ supply 
 TOPs between 214–243 days for prescriptions > 60 days’ supply 
 Live births between 341–370 days for prescriptions for 31-60 days’ supply 
 Live births between 37-400 days for prescriptions > 60 days’ supply. 
The duplicate NHI codes from these two datasets for each year were then investigated. 
If the last dispensing before the maternity outcome was for >30 days’ supply the 
maternity outcomes were considered as having occurred during the period related to 
isotretinoin use.  
3.3.2.1 Timing of Decision Support, Isotretinoin Prescription and 
Maternity Outcome  
Prescriptions are funded for 90 days from when they are written so for decision support 
to have been used at the time of prescribing, it would typically have been used within 90 
days of the first dispensing of that prescription. It is also possible within 90 days for 
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isotretinoin to have been freshly prescribed on a new prescription where decision 
support was not used. 
To determine the number of women whose prescriber used decision support at the time 
of prescribing isotretinoin and then went on to have a TOP or exposed birth I calculated 
the time between decision support use and each dispensing date. This identified the 
patients whose primary care isotretinoin prescriber used the BPAC decision support 
module in the 90 days prior to the prescription dispensing. I checked all dispensing 
dates, and determined if subsequent dispensings over the following 90 days were from 
the original prescription’s repeats, in which case decision support would not be used 
again, or if it was a new prescription where decision support could be used.  
5. Decision Support and Maternity Data Matched 
Table 8 shows the matched data from the Pharmaceutical Collection, PHO Enrolment 
Collection, Maternity Collection and the BPAC decision support usage data. 
Table 8: Data Source and Data Fields contained in Decision Support and 
Maternity data matched 
Data Source Data Field 
Pharmaceutical Collection Encrypted NHI 
Pharmaceutical Collection Sex Code 
Pharmaceutical Collection Last dispensing Date 
PHO Enrolment Collection Ethnic Code 
PHO Enrolment Collection Age at Dispensing 
PHO Enrolment Collection Deprivation Quintile 
BPAC Decision Support Usage Data  Encrypted NHI indicating Decision Support 
use 
BPAC Decision Support Usage Data  Date of Decision Support use 
NMDS Date Maternity Event Ended 
NMDS  ICD-10-AM Code* 
NMDS  Diagnosis Related Group codes* 
*Prior to 2012 NMDS data used Diagnosis Related Group codes and from 2012 the 
ICD-10-AM code was used. 
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The proportion of female patients whose care was guided by the BPAC Isotretinoin 
Decision Support module was found by filtering out males and removing duplicates to 
obtain the number of unique female NHI codes during the study period.  
To ensure no duplication or other anomalies in the data and to fully understand the 
‘story’ of each patient, the data was sorted by encrypted NHI code and each entry 
examined to fully determine each patient’s encounters. Examples to illustrate the 
processes used are in Appendix B.  
3.4 Ethical considerations  
This research involved the analysis of data that was originally collected as part of a 
hospital discharge, PHO enrolment, isotretinoin dispensing or use of a decision support 
tool to enhance patient care. However the information was never personally identifiable 
and the identity of the prescribers and patients in this study was hidden from the 
principal researcher and supervisors at all times. 
In collecting information for the NMDS, Pharmaceutical and PHO Enrolment 
Collection, the Ministry of Health is required to ensure the release of information 
recognises any legislation related to the privacy of health information, in particular the 
Privacy Act 1993 and the Health Information Privacy Code 1994117. In addition to this 
assurance, the BPAC Isotretinoin Decision Support tool specifically prompted the 
clinician to ask the patient if they consented to the use of the aggregated, non-
identifiable information from the form being kept for population based health research. 
If such consent was not granted, the patient’s care was not affected in any way and the 
clinician was still able to access the same support and resources through the tool. 
However, in this case, the information was not recorded in the BPAC database nor was 
the module used to document the consultation in the patient record. In this case the 
prescribing clinician would record the consultation using their usual manual processes. 
Where consent was granted and recorded at the time of using the module, it was 
considered ethically sound to use the non-identifiable data in this research. 
Ethical approval for this research was sought and granted from the University of Otago 
Human Ethics committee (Appendix C). A category B application was made as this 
project used encrypted NHI codes and de-identified data. Maori consultation was 
undertaken with the Ngai Tahu Research Consultation Committee (Appendix D). Jenny 
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McElroy is a current employee of BPAC CS LP but had no access to identifiable data at 
any time.  
3.5 Chapter Summary 
This chapter has described the design of the study and how the matching of the relevant 








This chapter will describe the results of analysis of the isotretinoin usage, maternity 
outcome and decision support datasets. 
4.1 Funded Isotretinoin Prescription Data 
Descriptive analysis of the people who received isotretinoin prescriptions for the study 
period 1 March 2007 – 1 March 2015 was made based on patient age, gender, ethnicity 
and deprivation level. 
Descriptive analysis of prescriber-type for the study period 1 March 2009 – 1 March 
2015 was made.  Prior to 1 March 2009 isotretinoin was funded only when prescribed 
by dermatologists so no analysis was done for the prescriber-type from 1 March 2007 to 
1 March 2009. 
4.1.1 Isotretinoin Access  
During the study period a total of 53,863 patients were dispensed 211,374 prescriptions 
for funded isotretinoin. On average these patients had 3.96 prescriptions each and 7.56 
isotretinoin dispensings. Isotretinoin is available in 10mg and 20mg capsule 
formulations only so to achieve a dose of 30mg, 50mg 70mg (etc) two prescriptions are 
required – one for 10mg capsules and one for 20mg capsules. The effect of this is that a 
count of the number of prescriptions for isotretinoin does not directly relate to the 
number of times isotretinoin is dispensed to unique patients.  
Frequent dispensing of pharmaceuticals is permitted in New Zealand where dispensings 
are for less than a month’s supply however the overall impact of these is small. For 
example in the year ending 28 February 2015 only 708 of the 54,688 dispensings were 
for 10 days’ supply or less meaning patients with repeated frequent dispensings of <10 
days’ supply made up around 1.3% of dispensings in that year. 
During the study period there were 26,388 prescriptions and 48,141 dispensings to 
patients with no NHI code. This constitutes 12.5% of the patients over the entire study 
period. However the impact of this diminished over the course of the study period: 
unidentified patients (no NHI code) contributed 18.8% of all funded dispensings in the 
first year data was available from 1 March 2007 to 29 February 2008. By the final year 
of the study period there were 890 unidentified dispensings or just 1.6%. 
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The number of patients accessing isotretinoin treatment increased steadily over the 
period. In the first year, 8,481 patients were dispensed isotretinoin and in the final year 
this number had increased to 13,846 patients, a 63.3% increase as shown in Figure 8.  
 
Figure 8: Number of Patients Dispensed Isotretinoin Annually 
While there were already increasing numbers of patients accessing isotretinoin each 
year prior to the funding change in 2009, the annual increase doubled during the year 
following the change. This annual increase in patient numbers returned the following 
year to an increase similar to the year prior to the change as shown in Table 9. 
Table 9: Percent Annual Increase in number of patients dispensed isotretinoin 
Year Annual increase % 
Year 1 8.9 
Year 2 18.1 
Year 3 9.4 
Year 4 5.7 
Year 5 1.7 
Year 6 4.0 


































The number of patients accessing isotretinoin in New Zealand continues to increase 
each year, although this rate of increase dropped steadily in the three years after the year 
of the change in funding.  
This section has shown access to isotretinoin increased over the study period with the 
largest annual increase in patients accessing isotretinoin being in the year following the 
funding change. 
4.1.2 Isotretinoin use by age 
Between March 2007 and February 2015, the most common patient ages at the time of 
isotretinoin being dispensed were 16 and 17 years as shown in Figure 9. The median 
age for isotretinoin to be dispensed was 19 years. 
 
Figure 9: Patient age at Isotretinoin dispensing 
People aged 10-30 years made up nearly 80% of patients who were dispensed 
isotretinoin although another 10% of prescriptions were for people aged 30-40 years.  
4.1.3 Isotretinoin usage by Gender 
Prior to the funding change on 1 March 2009 (Year 1 and Year 2 of the study period), 
57% of patients accessing isotretinoin in New Zealand were female and 43% were male 



















































Table 10: Proportion of patients dispensed isotretinoin annually by gender  
 Females % Males % Total 
Year 1 57 43 8,481 
Year 2 57 43 9,235 
Year 3 56 44 10,906 
Year 4 55 45 11,932 
Year 5 56 44 12,610 
Year 6 56 44 12,830 
Year 7 56 44 13,343 
Year 8 56 44 13,846 
There were no significant changes to the proportions of people accessing isotretinoin by 
gender following the funding change in March 2009 as shown in Figure 10. 
 
Figure 10: Gender of Patients Dispensed Isotretinoin 
4.1.4 Isotretinoin Use by Age and Gender 
The median ten year age band for males to access isotretinoin was 10-19 years and for 
females was 20-29 years both for the two year period prior to 1 March 2009 and in the 
six year period following 1 March 2009. In males, prior to the funding change on 1 
March 2009, the 10-19 year age group was the most common age to use isotretinoin and 








































most common age for females was 10-19 years and this showed a rapid decline in 20-29 
year old females as shown in Figure 11. Following the change in isotretinoin funding 
there was an increase in the number of females who were dispensed isotretinoin in the 
age groups >20 years. 
 
Figure 11: Age of Patients dispensed Isotretinoin from Mar 2007-Feb 2009 by 
gender 
Following the change in funded access to isotretinoin after 1 March 2009, the number of 
females accessing isotretinoin aged 20-29 did not decline as sharply from the peak use 
by 10-19 year old females as it had done when accessing funded isotretinoin required a 
dermatologist visit. Prior to March 2009, the number of female patients using 
isotretinoin in their 20s was 60% of the number who used it in their teenage years. From 
2009 to 2015 the number of females using isotretinoin in their twenties was 79% of the 
number using it in their teens. This demonstrates that females have been more likely to 
be prescribed or continue with isotretinoin after the age of 20 since 1 March 2009. 
4.1.5 Isotretinoin usage by Ethnicity 
There were changes in the proportional ethnicities of the people dispensed isotretinoin 










































European people accessing isotretinoin increased more than any other ethnic group and 
reflects the overall increase in isotretinoin use for this period of around 50%.  
 
Figure 12: Ethnicity of People Dispensed Isotretinoin 
However, the other ethnic groups of Maori, Pacific, Asian and MELAA have shown 
larger proportional increases as shown in Table 11.  
Table 11: Change in Ethnicity of Isotretinoin Patients since Funding Change 





7,059 397 164 619 145 853 9,237 
Mar2014-
Mar2015 
10,471 715 258 1,362 265 796 13,867 
% 
Increase 
48% 80% 57% 120% 83% -7% 50% 
*MELAA = Middle Eastern/Latin American/African 
The most notable proportional increase in use of isotretinoin during the study period is 






































numbers in the New Zealand PHO population. Despite the proportional increases in 
Maori of 80% and Pacific peoples of 57% taking isotretinoin from 2009 to 2014, they 
were still under represented compared to their numbers in the New Zealand population 
as shown in Table 12. 
Table 12: 2014-2015 Ethnic proportion compared to proportion of Isotretinoin 
Users 
2014 - 2015 European Maori Pasifika Asian MELAA* Other/Not 
Stated 
% of Isotretinoin 
users 
75.5 5.2 1.9 9.8 1.2 5.7 
% of PHO population 65.2 14.6 7.3 10 1.9 1.6 
*MELAA = Middle Eastern/Latin American/African 
4.1.6 Isotretinoin Usage by Deprivation Level 
The number of patients accessing isotretinoin in the most deprived groups, deprivation 
quintile 1 and 2, showed a 74% increase from 1 March 2009 to 1 March 2015. This was 
the largest increase with deprivation quintile 3 increasing 68% and deprivation quintile 
2 increasing 55%. The 50% increase in the least deprived group reflected the overall 
increase in numbers accessing isotretinoin in total. However as previous inequities in 
access to isotretinoin had been identified for the most deprived groups, the largest 






































Figure 13: Deprivation Quintile of Patients Dispensed Isotretinoin 
4.1.7 Days’ supply per dispensing  
Throughout the study period the most commonly prescribed length of supply for 
isotretinoin was 30 days. This is consistent with PHARMAC’s policy for isotretinoin to 
be dispensed in monthly allocations unless prescribers endorse prescriptions as a 
‘certified exemption’ or patients sign for an Access Exemption due to travel, relocation, 
physical mobility or transport issues.123 
There was a slight increase between the year ending March 2008 and the year ending 
March 2015 in the number of prescriptions dispensed for over 60 days’ supply from 
1.6% to 2.8% of all prescriptions respectively. This is illustrated for females in Figure 
14 and for males in Figure 15. 
 




























Figure 15: Days’ supply per Male Dispensing  
The significance of this change for females is the potential lack of contact with a health 
professional during the 2 months after dispensing to re-enforce the message about 
contraception being required during treatment and to discontinue treatment if pregnant. 
Females consistently collected more supplies of greater than 30 days than males 
although the difference was small.  
4.1.8 Isotretinoin Usage by Prescriber-Type  
The number of patients accessing isotretinoin from dermatologists has declined steadily 
since funded access was widened to include other prescribers with a Special Authority. 
In the year ending 28 February 2015 GPs prescribed isotretinoin to 50% more patients 
than dermatologists. There has been a sustained trend of fewer dermatology prescribers 
and more GP prescribers since the funding change on 1 March 2009.   
Although application for Special Authority to prescribe isotretinoin must be made by a 
dermatologist, GP or nurse practitioner, other prescribers continue to prescribe funded 
isotretinoin with a Special Authority.  Although dermatologists and GPs are by far the 




























isotretinoin prescribed by other prescribers each year. The number of Unknown 
prescriber type has decreased over the study period as shown in Figure 16. 
 
Figure 16: Patients Dispensed Isotretinoin by Prescriber Type 
In the twelve months prior to 1 March 2009, 8,062 patients were dispensed isotretinoin 
that had been prescribed by a dermatologist and the number of people prescribed 
isotretinoin by a dermatologist decreased by around 1,000 patients in the first year 
following the funding change. This first year after GPs were able to prescribe funded 
isotretinoin saw 3,425 patients access the medication this way and this number 
increased by 53% in the following year and 24% in the year to 1 March 2012 as shown 
in Table 13. The increase continued in the following three years so that by the year 
ending 1 March 2015 more patients were prescribed isotretinoin by their GP than had 
obtained it from a dermatologist prior to the funding change. 
Table 13: Percent Change in Patients Dispensed Isotretinoin by Prescriber Type 



















Dermatology 8,062 7,104 6,273 5,887 5,723 5,709 5,486 
%  change  -12% -12% -6% -3% - -4% 










































% change   +53% +24% +7% +9% +9% 
4.2 Use of BPAC Decision Support Module 
This section will describe the use of the BPAC Decision Support Isotretinoin module in 
New Zealand for the period when usage data was available between 1 January 2007 and 
30 June 2015.  
4.2.1 Use of BPAC Decision Support Module by Gender 
From 1 January 2007 to 30 June 2015 there were 63,054 isotretinoin dispensings for 
56,919 patients (unique NHI codes). Of these patients, 31,261 were females and 25,655 
were males, with 3 of unknown gender. There were 2,932 females and 2,549 males 
whose prescriber used decision support to guide their isotretinoin prescribing (9.4% and 
9.9% of female and male patients respectively). 
These numerical observations do not directly provide information about the impact on 
maternity outcomes of decision support use unless the timing of this decision support 
use is considered in relation to a maternity outcome. For example, a GP using decision 
support after an isotretinoin-related maternity event has not helped to avoid that event. 
4.3 TOPs in Women Dispensed Isotretinoin 
This section will describe the TOPs in women dispensed isotretinoin during the study 
period from 1 March 2007 to 28 February 2015. This crude data will be converted to a 
TOP rate per 1,000 females accessing isotretinoin and compared to the TOP rate for all 
females aged 15–44 in New Zealand. The TOP rate for all females in New Zealand is 
not available, but less than four percent of prescriptions for isotretinoin during the study 
period were to females aged under 10 years or over 50 years. No females aged under 10 
years or over 50 years who were dispensed isotretinoin during the study period had a 
subsequent TOP.  
4.3.1 Isotretinoin prescriptions and TOP 
Across all study years there were 161 TOPs that could be matched with an isotretinoin 
dispensing in the preceding six months (seven months if 60 days’ supply of isotretinoin 





Figure 17: TOPs in Women Dispensed Isotretinoin 
4.3.2 Comparative TOP Rate for Isotretinoin Users 
By dividing the number of TOPs in women dispensed isotretinoin in Figure 17 by the 
total number of females who accessed isotretinoin in each year as in Figure 10, a crude 
TOP rate per 1,000 females can be calculated. The crude TOP rate for all females aged 
15–44 years in New Zealand over the study period declined from 19.7 to 14.2.124 For 
women who had a prescription for isotretinoin in the preceding six months this rate 
dropped from 4.6 to 3.3 as shown in Figure 18. 
 


























































4.3.3 TOP Rates by Prescriber Type 
The absolute number and rate of TOPs per 1,000 females dispensed isotretinoin for each 
prescriber-type are shown in Figures 19 and 20. 
 
Figure 19: TOP by Prescriber Type 
 







































































The TOP rate for Dermatology prescribers of isotretinoin has ranged between 1.9 and 
3.4 per 1,000 females treated since the year ending March 2009. For GP prescribers 
since the funding change this rate has been marginally higher between 2.1 and 3.7. This 
compares to a crude TOP rate for all females aged 15–44 that has dropped from 19.3 to 
14.2 over this time. 
In the year ending February 2010 there were 5 TOPs to women dispensed isotretinoin 
during the related period for both ‘Other Prescribers’ and for ‘Dr No Specialty Known’. 
In this year ‘Other Prescribers’ wrote isotretinoin prescriptions for 285 female but only 
35 patients were recorded as ‘Dr No Specialty Known’. This equates to a TOP rate per 
1,000 females treated of 17.5 for ‘Other prescribers’ and 142.9 for ‘Dr No Specialty 
Known’ reflecting a relatively high number of TOPs for a small number of females 
treated . These rates subsequently dropped to below the crude rate for all females 
although remained higher than for GPs and Dermatology in the following three years. 
There were no events attributed to these prescribers in the year ending March 2014. The 
rate in the year ending 2015 was slightly higher than GPs and dermatologists, although 
more in line with their prescribing than it had been previously. 
4.4 Live Births Exposed to Isotretinoin 
This section will describe the number of live births that occurred to females who had 
isotretinoin prescriptions dispensed within the guideline period.  
4.4.1 Isotretinoin prescriptions and Exposed Live Births 
Live births where the infant was potentially exposed to isotretinoin during pregnancy 
have been identified and shown by prescriber type in Figure 21. This study suggests up 
to 16 births per year in New Zealand may be exposed to isotretinoin in-utero. 
Dermatologist, GP and other prescribers’ prescriptions contribute to these exposures. 
Since 1 March 2011 GPs have prescribed isotretinoin for more patients each year than 
dermatologists and since this time there have also been more potentially exposed live 




Figure 21: Live Births Exposed to Isotretinoin 
NB: Two births following GP prescriptions in the year ending March 2013 occurred 
very closely to the guideline period of 400 days at 389 and 399 days following a 
prescription for isotretinoin. It is possible these women adhered to guidelines but infants 
were born slightly early however they have been included in these totals as they fit the 
guideline criteria.  
Figure 22 shows the rate of exposed live births per 1,000 females treated for the 
different prescriber types illustrating lower rates for dermatologists and GPs than the 








































Figure 22: Rate of Exposed Live Births per 1000 Females Treated by Prescriber 
Type 
4.5 Decision Support Data 
This section will describe how many of the patients who had TOPs and potentially 
exposed live births following isotretinoin treatment had the BPAC Decision Support 
module used and the number of patients where it was used for the related prescription. 
The rate of these events per 1,000 women treated with isotretinoin will be calculated. 
4.5.1 TOP rate for prescribers using Decision Support 
There was one TOP during the linked period following isotretinoin dispensing when the 
prescriber used decision support for that isotretinoin prescription in the year ending 
March 2011 and there were two in each year ending March 2012 and 2014 as shown in 
Figure 23. There was one additional TOP in the year ended 1 March 2011 and another 
in the year ended 1 March 2015 where decision support had been used for this female 

















































Figure 23: TOPs in women Dispensed Isotretinoin where Decision Support was 
used 
The decision support module was used for 2,293 of the 21,499 females who had 
isotretinoin prescriptions between 1 March 2009 and 1 March 2015 which allowed a 
TOP rate per 1,000 females treated to be calculated for those women who had ever had 
decision support used to guide their prescribing as shown in Figure 24. 
 
 







































































4.5.2 Exposed Live Birth Rate for Prescribers using Decision Support 
Of the 71 potentially exposed births since the funding change on 1March 2009, there 
were two instances in the year ended 1 March 2014 and one in the year ended 1 March 
2015 where the BPAC Decision Support tool was used prior to the linked isotretinoin 
prescription as shown in Figure 25. There was one additional potentially exposed birth 
in the year ended 1 March 2014 where decision support had been used for this female 
previously but not for this prescription.
 
Figure 25: Potentially Exposed Live Births where Decision Support was used 
Figure 26 shows the rate of potentially exposed live births per 1,000 females treated 
with isotretinoin for all females treated with isotretinoin and compares this to the rate 
where decision support was not used, where it has ever been used for that woman, and 





























Figure 26: Potentially Exposed Live Births per 1,000 Females Treated 
4.6 Chapter Summary  
This chapter has described the results of the data analysis. The usage and maternity 
outcomes in women dispensed isotretinoin during the linked period were addressed. 
This was done by age, gender, ethnicity, deprivation level and prescriber-type. The links 
between maternity outcomes and the use of decision support were also described. A 















































5 Discussion and Recommendations 
This chapter will review the results of this study in light of the currently known 
information about isotretinoin access and TOPs and exposed live births occurring in 
women who have taken isotretinoin during the linked period. The recommendations and 
areas for future research that have come out of the study are presented. The limitations 
and strengths of the study are also discussed.  
5.1 Main Results 
The number of patients accessing isotretinoin continued to increase year on year from 1 
March 2007 to 1 March 2015 although the immediate increase in isotretinoin use after 
the funding change rapidly dropped off to rates similar to before the change. This 
suggests more restrained increase in isotretinoin use after that time and reflects patterns 
previously identified in other moves to improve healthcare access.125 
It is not clear if this increased use reflected an increasing awareness and therefore 
demand for oral acne treatment or was meeting a previously unmet need. Isotretinoin 
has remained the only agent of its type for the treatment of severe acne, and moderate 
acne after antibiotics and where topical agents have failed. No new alternative agents 
have been introduced to the market over the study period that might have impacted the 
number of patients accessing isotretinoin.  
This study has confirmed the differences found elsewhere in the age distribution of 
males and females seeking medical attention for acne also occur with isotretinoin in the 
New Zealand context.89 Teenage males are the group who access isotretinoin the most 
by age and gender. Since isotretinoin also became funded through GPs and nurse 
practitioners, proportionally more females have continued to use isotretinoin after the 
age of 20 than they had previously. This could potentially reflect that the additional GP 
prescribers were less reluctant to prescribe isotretinoin to sexually active females over 
20, or could reflect the widening use of isotretinoin in milder acne which females of this 
age are more likely to have (see 1.1.3.4 above). This is significant because females are 
more likely to be regularly sexually active in their 20’s than they are between the ages 
of 10 and 19. Increased access and use of isotretinoin by females of child-bearing age 
who are sexually active must address the teratogenic risks of this agent to ensure its safe 




Although starting from an under-represented proportion of the population, ethnicities 
other than European have made proportionally larger increases in the numbers accessing 
isotretinoin since the funding change on 1 March 2009. Although the largest absolute 
increase in isotretinoin users are European, this is proportional to the overall increase in 
its use during the study period. By contrast the proportion of Asians has increased 120% 
compared to the proportion of Asian isotretinoin users prior to the funding change. This 
might have had more significant implications on the TOP rate of isotretinoin users and 
be an ongoing issue for the future if the TOP rate for Asians which was previously the 
highest ethnicity, had not declined to be similar to that of Maori and Pacific women 
since 2012.124 
The percent of people dispensed isotretinoin who identify as Maori and MELAA has 
increased 80% over the years since the funding change while the overall increase in 
access has been 50%. Pacific people had the smallest proportional increase in 
isotretinoin use other than Europeans at 57%. The change in funded isotretinoin has 
helped address inequities for access to isotretinoin for non-European ethnicities in New 
Zealand. 
While no New Zealand data exists to confirm the prevalence of acne in Maori and 
Pacific people, these increases may have gone some way to addressing the previously 
recognised inequities of isotretinoin access to these ethnicities. However the largest 
increase in the absolute number of people accessing isotretinoin in any one ethnicity 
was seen in Europeans.  This may reflect a greater perception of ‘problem acne’ in fairer 
skins where the redness from inflammation is more noticeable, cultural differences in 
the importance of acne and fewer barriers to accessing health services in Europeans.  
The most deprived people have made proportionally larger increases in numbers 
accessing isotretinoin since the funding change suggesting the change has helped 
address inequities for access to isotretinoin for the most deprived groups in New 
Zealand. The trend for females to collect more than 30 days’ supply of isotretinoin at 
once should be discouraged in sexually active females of child bearing age unless a 
negative pregnancy test is required monthly. 
The introduction of GP prescribing of funded isotretinoin in New Zealand has made this 
treatment for severe acne available to more patients than were accessing it previously 
through dermatologists. In New Zealand GP and dermatologists are now the dominant 
prescribers of isotretinoin. 
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For the purposes of this study, a TOP within 6 months of an isotretinoin prescription or 
an isotretinoin-exposed live birth are both considered to be adverse health outcomes. 
TOPs continue to occur in New Zealand during the period of time following isotretinoin 
dispensing that suggests they may be related to isotretinoin use. The rate for these TOPs 
per 1,000 females is roughly 20% the TOP rate for all females aged 15-44 in New 
Zealand. While it would be ideal to avoid any unplanned pregnancy during the use of a 
teratogenic acne treatment, the lower rate compared to all females indicates caution is 
being used in prescribing isotretinoin in New Zealand. Any steps to further consistently 
reduce this rate, while maintaining access to a very effective treatment when it is 
needed, would contribute to even safer use of this teratogenic medicine. 
The female patients of dermatologist and GP prescribers of isotretinoin demonstrate 
similar rates of TOP following isotretinoin dispensing. This was a surprise finding as 
GPs’ experience of prescribing and discussing contraception with women had been 
considered as one reason their prescribing might result in even fewer pregnancies 
following isotretinoin dispensing than dermatologists. Perhaps this finding mirrors the 
previous finding in the US where GPs were shown to be the second most frequent 
providers of prevention and counselling categories including issues related to obstetrics 
and gynaecology when compared to other office-based medical specialties.126 
The total number of TOPs following isotretinoin dispensing identified in this study were 
significantly lower than the previous study for the year ending June 2008 by Moodie et 
al.40 I am unable to examine the raw data from the previous work and cross-check it 
against my own so cannot validate their methods. In particular it would be valuable to 
confirm each of the 39 TOPs reported by their analysis was a separate maternity event 
rather than being the number of isotretinoin prescriptions where a TOP occurred within 
the following six months.  
In the first few years when isotretinoin could be prescribed by clinicians who were not 
dermatologists, the women whose prescriptions were written by ‘other prescribers’ and 
‘doctors whose specialty is unknown’ went on to have a TOP following isotretinoin 
more often than women whose isotretinoin-prescriber was a GP or dermatologist. The 
number of prescriptions from these other or prescribers of unknown specialty was small 
suggesting prescribers who were familiar with the use of isotretinoin may have offered 
better support and guidelines to women about the need to use two forms of 
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contraception if they are sexually active and that they should not become pregnant while 
they are undergoing treatment and for 30 days after. 
While isotretinoin is prescribed to sexually active women of child-bearing age there is a 
risk of babies being exposed to this teratogen in-utero. Minimising this risk should 
remain a key component of appropriate prescribing in our communities. This study 
demonstrated certain prescriber-types potentially expose a disproportionate number of 
babies to isotretinoin in-utero suggesting regulators should carefully examine how these 
prescribers can be supported to remove or minimise this risk.  
Although the total numbers are small, women who have had the BPAC isotretinoin 
decision support module used are less likely to have a TOP within six months of an 
isotretinoin prescription and are less likely to have a baby delivered that has potentially 
been exposed to isotretinoin in utero. This outcome is even more pronounced if the 
BPAC module was used for the related isotretinoin prescription.  
As there were 162 TOPs within six months of an isotretinoin prescription in the six 
years following the funding change on 1 March 2009 and 9.4% of females had the 
BPAC isotretinoin decision support used for them, it might be expected there would be 
16 TOPs where the module was used. There were five TOPs where decision support had 
been used which suggests 11 terminations of pregnancy may have been avoided by the 
use of the module during this time. Alternately, if every prescriber had used the BPAC 
isotretinoin decision support tool to guide his prescribing to females, the number of 
TOPs following isotretinoin could have been reduced from 162 to 50. 
There were 69 potentially exposed births in the six years following the funding change 
and if 9.4% of females had decision support used, seven births could be expected where 
the module was used. There were three births where decision support was used for the 
isotretinoin prescription involved which suggests exposure to isotretinoin in utero may 
have been avoided for four children. If all prescribers had used the BPAC decision 
support tool, the number of babies exposed to isotretinoin could possibly have been 
reduced from 69 to less than 30. 
This study has demonstrated improved maternity outcomes where the BPAC 
isotretinoin decision support module is used to guide prescribers. However the use of 
any guideline support tool that is optional may reflect the more cautious, guideline 
driven practice of the prescribers who chose to use it. Improved access to isotretinoin 
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decision support for all prescribers and steps to increase its use every time isotretinoin is 
prescribed may help reduce adverse health outcomes for women taking this teratogenic 
medicine and their babies. 
5.2 Recommendations 
With the availability of such comprehensive and valuable data about outcomes from the 
New Zealand health system the challenge is to convert this knowledge into wisdom that 
transforms the future.127  Funding for isotretinoin through GPs has increased its 
availability to lower socio-economic groups and ethnicities that have previously faced 
inequitable access barriers.  This knowledge could be applied to other pharmaceuticals 
where current funding is only through specialist-only prescribing and alternative 
treatments do not exist. Where there is a likely benefit for more patients to have 
improved health from increased access to these restricted agents, but little potential for 
harm, the widening of funded access to include vocationally registered GPs and nurse 
practitioners should be explored.  
Prescribers other than GPs and dermatologists do not prescribe isotretinoin often but 
when they do, the maternity outcomes for their female patients are poorer. Isotretinoin 
may be used more safely when funded access is restricted to dermatology and 
vocationally registered GP and nurse practitioner prescriptions only. 
The BPAC Isotretinoin Decision Support tool has helped facilitate safer prescribing of 
isotretinoin. This module was developed in 2009 and has had consistent use, but for less 
than 10% of all isotretinoin patients since that time. Investment in updating the module 
to a format reflecting other decision support tools commonly used in 2016 that are more 
readily adopted by clinicians has the potential to lead to safer maternity outcomes for 
female patients and avoid babies being exposed to this teratogen.  
The widespread use of decision support tools that engage female patients and 
prescribers in understanding when a medicine may cause birth defects, and that 
promotes the ongoing commitment to two forms of contraception during treatment, has 
the potential to lead to safer prescribing of all teratogenic agents. Optimal benefit is 
most likely to be achieved if this support is implemented every time a teratogenic agent 
is prescribed, and re-enforced with subsequent pharmacy dispensings. 
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5.3 Areas for Future Research 
 The isotretinoin maternity dataset obtained for this study contains the ICD-10-
AM codes O00 to O03 which are ectopic pregnancies, hydatidiform moles, other 
abnormal products of conception and spontaneous abortions. Future analysis of 
this data is possible to determine the adverse maternity outcomes in New 
Zealand women taking isotretinoin for the 15 month period following oral 
treatment however this did not form part of the current study. 
 The isotretinoin Usage dataset obtained for this study could also be analysed to 
understand changing doses and treatment periods over the study period. With the 
evidence for a cumulative dose regime having been challenged since isotretinoin 
was first registered in New Zealand, it would be valuable to quantify current 
prescribing patterns to identify if lower doses are being used for longer 
treatment periods. This analysis would inform future measures for understanding 
and managing adverse effects over extended time periods. 
 Future qualitative research into the obstacles and enablers to accessing 
isotretinoin treatment and concurrent effective contraception across all 
ethnicities and deprivation levels is an important area for future research. This 
understanding would inform a review of the pathways to isotretinoin access with 
the goal of achieving equitable and safe access for this very effective agent.  
 The isotretinoin maternity dataset contains information about the ages, 
ethnicities, District Health Boards (DHBs) and deprivation levels for the women 
who had TOPs or exposed live births following isotretinoin treatment. Further 
analysis of these demographics would identify areas with greater need for 
support in managing the teratogenicity of isotretinoin and ensure efforts to 
address these needs are directed appropriately.  
 Currently no data is available about where patients get information on 
isotretinoin teratogenicity or the level of patient understanding of the issue. 
Qualitative research addressing what information patients want and how they 
would like to receive it would help ensure the most effective delivery so future 
harms can be minimised. 
 The patterns of usage for the current BPAC decision support module by gender, 
ethnicity, deprivation level and DHB of clinician and patient may allow better 
Jenny McElroy    89 
 
understanding of the barriers and facilitators to its use when prescribing 
isotretinoin. Currently there is no data available to clarify when prescribers use 
decision support and why they don’t use it. Qualitative research to determine 
what prescribing support isotretinoin prescribers want and how it should 
integrate with current processes will also inform the development and 
implementation of the most effective prescriber support possible. 
5.4 Strengths of this study 
This is a population based study analysing all the New Zealand population data for eight 
years. The NHI code is the primary enabler to allow this matching of data from different 
sources. The ability to link data is particularly strong because of the existence and 
widespread use of the NHI code throughout the New Zealand health system. The 
observations made in this study illustrate the value of New Zealand data for the purpose 
of analysing links between healthcare and outcomes.  
As well as the matching of data from a number of different sources, this study also 
included individual review on a case by case basis, driven by original research 
questions, to identify any anomalies and to verify the links. It is descriptive research but 
it is very comprehensive and replicable. It also meets many of the recommended goals 
of evaluation for risk-minimisation programmes in that it has been without extra burden 
on either healthcare professionals or patients and has used existing data sources to 
measure outcomes in a practical, feasible and easy to collect manner.116 
The opportunity to analyse the impact on health outcomes of a change in funding for an 
established medication is rare. The opportunity to do so with such detail on a whole 
nation’s data is even more so. As far as I have been able to ascertain there is no other 
published literature indicating a whole nation’s isotretinoin dispensing data has ever 
been analysed and matched with TOP and maternity data in such careful detail to 
analyse the impact of a funding change. With varied global approaches to managing the 
teratogenic risk of isotretinoin, this study adds to the universal understanding of how 
prescriber type impacts these outcomes.  
This study meets the recommended requirements of an evaluation method for a risk-
minimisation measure in that it is tailored to specific safety concerns, the actual 
decision support tool used and the drug involved.128 It is the first time the outcomes for 
female patients whose prescriber did not use an isotretinoin decision support tool to 
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guide their prescribing have been compared with the outcomes in patients whose 
prescribers did voluntarily use the tool.  
The study illustrates the potential for decision support to successfully guide the 
prescribing of teratogenic agents without increasing barriers to access. As a minimum, 
the steps in the decision support module relating to female patients understanding this 
drug can cause birth defects, the need for contraception and the advice not to get 
pregnant for 30 days as minimum has clearly been shown. The outcomes of this study 
may encourage health planners to re-think regulation that allows prescribers who are not 
familiar with isotretinoin to prescribe it. This therefore becomes valuable to New 
Zealand health managers to inform future approaches to managing teratogenic agents.  
In addition, with various approaches to prescribing isotretinoin and other teratogenic 
agents globally, this study demonstrates the relative impacts prescriber-type and the use 
of decision support can have on maternity outcomes. Other nations whose standard of 
clinical care is similar to the New Zealand situation may consider how this may be used 
to improve the outcomes in their context. 
5.5 Limitations of this study 
1. TOP statistics reported by Abortion Supervisory Committee include all legal 
induced TOPs in New Zealand but despite a recommendation that private TOP 
clinics include NHI codes in their reporting this has not occurred. In the most 
recently available data from 2014 there were 13,137 legal TOPs in New Zealand 
with 931 (7%) of these at the Auckland private clinic. These procedures are not 
included in the data from the NMDS which is for publicly funded services only and 
none of these 7% have NHI codes so cannot be linked to isotretinoin prescribing. 
Similarly for the last three years Tauranga Family Planning Clinic has been doing 
medical TOPs which do not require a hospital discharge so are not included in this 
sample. 
2. Some of the women who chose to attend the private Auckland TOP clinic may have 
done so as they were ineligible for funded healthcare in New Zealand. These same 
women would not receive funded prescriptions for isotretinoin and therefore their 
prescriptions would also not form part of the Pharmaceutical Collection data. This 
means the true number of TOPs in New Zealand following isotretinoin use may be 
higher than the publicly funded figures represented in this study. 
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3. The number of unknown NHI codes limits the accuracy of this data as all 
demographics and any NMDS maternity event matches are lost for these 
dispensings. The number of these Null NHI code dispensings has decreased over the 
study period as shown in Figure 27 meaning maternity events following isotretinoin 
prescriptions will have been under reported in the earlier part of the study period.  
During the entire study period from 1 March 2007 to 28 February 2015 there were a 
total of 26,388 prescriptions and 48,141 dispensings where the NHI code was not 
available. This constitutes 12.5% of the patients over the entire study period.  
The impact of prescriptions with Null NHI codes diminished over the course of the 
study period with 33.4% of prescriptions having a Null NHI in the year ending 1 
March 2009, 16.3% in the year ending March 2010 and 12.3% in the year ending 
March 2011. Since that time, the prescription data has contained less than 10% Null 
NHI codes. 
In the year ending 1 March 2009 the proportion of Null NHI codes was 33.4% of all 
dispensing data and, as this was nearly all dermatologists’ prescribing, reflects the 
lack of NHI code use by these prescribers at the time. As GP prescribing of 
isotretinoin has increased, this proportion of unknown NHI codes has significantly 
decreased to be just 1.6% of all dispensings in the year ending 1 March 2015. 
 













4. It is realised that a number of pregnancies do not last 280 days and this may have 
meant this study over-estimated the potential exposure to isotretinoin during 
pregnancy. However, pre-term birth is considered an adverse pregnancy event in 
itself, some pregnancies go beyond term, and many patients miss days of medication 
after picking up prescriptions meaning they are still taking medication beyond the 
expected treatment period. Considering these possibilities, this study has 
implemented the stated time periods as there may be both under-estimates and over-
estimates which could cancel each other out.  
 
5.6 Chapter Summary 
The study was concluded in this chapter with a discussion of the strengths and 
limitations of this research. The recommendations that were made after completion of 
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Appendix A: Analytic approach to Ministry of Health isotretinoin 
prescribing and maternity data 
 
The cleaned data from Maternity Dataset 2 was analysed as follows: 
1. First I filtered out all maternity events using the ‘days between’ column where 
any maternity event was more than 183 days (i.e. 6 months) after an isotretinoin 
prescription. 
2. This gave the NHI codes for women with maternity events within six months 
and I filtered out all events that were not TOPs. (The same process was used later to 
analyse the exposed pregnancies where I filtered to obtain the potentially exposed live 
births in the appropriate timeframes). 
3. I copied this cohort to a new worksheet entitled ‘TOP < 183 days’ from where I 
could sort by dispensing date. This allowed all the TOPs from each 12 month period 
from 1 March 2007 to 1 March 2015 to be counted. 
4. I also wanted to include any TOP events between 183 and 243 days where more 
than 30 days’ supply of isotretinoin had been dispensed, to reflect the continued 
exposure from larger dispensing quantities. To do this I filtered the dataset in the same 
way to identify NHI codes where the days between isotretinoin dispensing and TOP 
were 183-243 days. 
5. For each 12 month period ending 1 March, I matched this list of women with a 
TOP in 6-8 months against the women who had been dispensed more than 30 days’ 
supply in each year. By matching duplicates, I found NHI codes appearing in both lists 
and checked if they had a TOP within 213 days with 31 - 60 days’ supply or 243 days 
with 61 - 90 days’ supply. This identified an additional 4 linked events for the entire 




Appendix B: Worked examples of data linking 
 
Four examples are detailed below to illustrate the data linking processes that were used 
and different outcome scenarios: 
1. TOPs where Isotretinoin had been Dispensed 
Example 1: Data illustrating identification of a TOP where Isotretinoin had been 
Dispensed 
 
In the example above, the ‘dispense date’ column shows isotretinoin was dispensed 7 
times between 24 November 2011 and 15 October 2012. A GP wrote six prescriptions 
and a dermatologist provided one. 
Over this one-year period this patient had one TOP on 8 February 2013, another TOP 
on 15 November 2013, and a spontaneous abortion on 1 December 2013. The first TOP 
was 116 days after a prescription for isotretinoin and so it was counted as being during 
the period that was potentially linked to isotretinoin. 
The second TOP was > 396 days after her most recent prescription for isotretinoin so it 
was not counted as being likely related to isotretinoin. There are no dates in the 




2. Potentially exposed live birth 
Example 2: Data illustrating identification of a potentially exposed live birth 
 
In this example isotretinoin was dispensed on 21 June, 26 July, 10 September, and 5 
November of 2012 and on 21 January 2013. After a break there were then two more 
dispensings on 8 May and 25 July 2013. 
The July dispensing was followed four weeks later by a TOP on 21 Aug 2013, after 
which she was dispensed her final dermatologist prescription in the study period on 19 
Nov 2013 and then a GP-prescribed dispensing on 7 March 2014. This dispensing was 
almost exactly 12 months before a live birth on 3 March 2015 so would have been 
within the guidelines if it was for 30 days’ supply. However the usage data showed this 
GP dispensing was for 84 days’ supply, so if this woman took all dispensed doses, 
waited four weeks before becoming pregnant, and had a full term pregnancy, a baby 
born before 7 April 2015 would potentially be exposed to isotretinoin. Her baby born on 
3 March 2015 could potentially have been exposed at the critical time of 2-5 weeks post 
conception.49 
Having completed the ‘stories’ of patients who had maternity events within 15 months 
of an isotretinoin prescription I counted the number of events. I identified all the NHI 
codes for women who had a TOP within eight months of an isotretinoin prescription 
and all live births within 400 days of an isotretinoin prescription during the study 
period. This conclusion has been supported by subsequent further checks completed 




3. Example of Decision Support use and TOP 
Example 3: Data illustrating identification of Decision Support use and TOP 
 
 
In the example illustrated above isotretinoin was prescribed by a dermatologist in 2011 
and by a GP in August and October 2013. Decision support was used on 12 November 
2013 and a prescription presented on 27 November 2013. Repeat dispensings were 
collected 8 January 2014 and 14 February 2014 and the patient had a TOP on 21 
February 2014. In this example isotretinoin was dispensed more than 90 days after 
decision support was used and a TOP occurred a week after the final dispensing. 
4. Example of Decision Support use and exposed live birth 
Example 4: Data illustrating identification of Decision Support use and a 
potentially exposed live birth 
 
In this example isotretinoin was dispensed on 13 December 2013 and 15 January 2014 
for 30 days’ supply each time with no repeats. Decision support was used 23 January 
2014 but the first dispensing of this new prescription did not occur for 53 days (nearly 
eight weeks) until 18 March 2014. As the prescription included two repeats which were 
collected 26 April 2014 and 30 May 2014, it was over four months (126 days) after 
decision support was used that the final dispensing of this prescription was made. The 
woman then went on and had a live birth on 1 March 2015 which was 275 days later – 
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